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Abstract 
 
 
Cardiovascular disease continues to be the leading cause of morbidity and 
mortality worldwide with an estimated 17 million annual deaths. A majority of 
cases are attributed to disease affecting the vascular system including 
arterial, venous and lymphatic vessels. Despite progress in understanding the 
molecular bases of vascular development and disease, the role of chromatin 
modifying enzymes in vascular processes remains ill defined. Here we show 
that the histone-modifying enzyme Hdac3 is a critical regulator of lymphatic 
vascular development. Endothelial specific loss of Hdac3 in mice affects the 
development of lymphovenous and lymphatic valves resulting in aberrant 
blood lymph separation, lymphedema and complete lethality. We demonstrate 
that Hdac3 functions in a flow responsive manner to regulate the expression 
of Gata2, a transcription factor essential for lymphatic valve development. In 
response to flow, transcription factors Tal1, Ets1/2 and Gata2 recruit Hdac3 to 
an evolutionarily conserved intragenic enhancer of Gata2 gene. In turn, 
Hdac3 recruits p300, a histone acetyl transferase, to render activation of the 
Gata2 enhancer, and thus promotes Gata2 transcription. Together, our 
findings demonstrate the molecular basis by which cell extrinsic and intrinsic 
cues cooperate to regulate lymphatic development. 
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CHAPTER I: Introduction 
The cardiovascular system, composed of a central pump (the heart) and a 
network of conduits (the blood vessels), is the first functional organ system to 
develop during mammalian embryogenesis. The heart and blood vessels 
collaborate to send oxygen- and nutrient-rich blood throughout the embryo to 
support and sustain growth and development. Initial assembly of the vascular 
system occurs through vasculogenesis (Risau and Flamme, 1995), a complex 
process whereby endothelial cells, which will eventually line all vessels in the 
body, differentiate from the mesoderm to form a primitive plexus of blood 
vessels. Subsequently, angiogenesis, remodeling, expansion, and maturation 
of this primitive plexus forms a hierarchical network of vessels of varying 
calibers and composition for efficient nutrient delivery and waste removal 
throughout the body (Potente et al., 2011; Risau, 1997). The blood vascular 
system is further differentiated molecularly and functionally into two serial 
systems - a pre-capillary high-pressure arterial system and a post-capillary 
low-pressure venous system. In parallel, a low-pressure system of channels, 
the lymphatic vasculature develops through a process of lymph-angiogenesis 
to complement the function of the blood vessels (Alitalo et al., 2005; Tammela 
and Alitalo, 2010). Defective development of the blood and/or lymphatic 
vascular system can result in diseases ranging from embryonic death to 
congenital vascular anomalies manifesting at various stages of postnatal life  
(Uebelhoer et al., 2012; Wassef et al., 2015). Although substantial progress 
has been made in defining the molecular regulators of arterial and venous 
vessel development, the lymphatic system is relatively understudied. 
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Lymphatic vascular development and disease 
The lymphatic system encompasses a tiered network of channels culminating 
in blind-ending capillaries and constitutes an essential part of a functioning 
mammalian circulatory system. In addition, lymph nodes, which are tissue 
structures composed of T and B immune cells embedded in a stromal 
network, are inter-positioned within larger lymphatic vessels (Blum and Pabst, 
2006). The lymphatic system performs multiple tasks including draining 
excess protein-rich interstitial fluid back into the systemic circulation, 
trafficking immune cells from tissues to lymph nodes, for antigen presentation 
and immune surveillance, and transferring lipid-rich chyle from the intestine to 
the blood (Swartz, 2001).    
             Primary lymphedema encompasses disorders arising due to failure in 
the development of the lymphatic system (Mortimer and Rockson, 2014). 
Global prevalence is estimated at 1:6000 in the general population, including 
syndromic and non-syndromic cases of primary lymphedema. Mutations in 
several regulators of lymphatic endothelial cell structure and function including 
growth factors, cell surface proteins, cell signaling molecules and transcription 
factors have been implicated in human patients, suggesting genetic 
heterogeneity (Brouillard et al., 2014; Michelini et al., 2018). In addition, genes 
identified so far have been shown to regulate multiples aspects of lymphatic 
development. Despite recent progress in identifying disease-causing genes, 
the precise mechanism by which their expression and/or function during 
lymphatic development are regulated is not clear. 
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Historically, descriptions of the lymphatic system can be traced back to 
the ancient Greeks; however, it was not until the 17th century that a more 
systematic study of the lymphatics took place (Loukas et al., 2011). Gasparo 
Aselli, an Italian anatomist, through the dissection of abdomens of dogs in 
unfed and fed state, described the presence of ‘veiue albae aut lacteae’ in the 
intestine or ‘vein like vessels that lack pulsation and transport a milky fluid’ 
within them. He also described the presence of valves within these vessels 
and inferred that they might help prevent fluid backflow (Loukas et al., 2011). 
Subsequently, scholars of the 18th-19th centuries described the detailed 
anatomy of the lymphatic system and examined the primary significance of 
the lymphatics in health and in disease. 
During the early 20th century, two groups put forth theories addressing 
the developmental origin of the lymphatic system. Using ink injection into 
embryos, Florence Sabin deciphered that the lymphatic system originated by 
budding from the centrally located cardinal vein and grew peripherally to all 
other tissues (Sabin, 1909). In contrast, Huntington and McClure postulated 
that lymphatics develop from peripheral tissues and then make connections 
with the central venous system based on wax reconstruction of cat embryos 
at different stages of development (Huntington and McClure, 1910). Almost a 
century later, the use of modern molecular and genetic tools, largely support 
Sabin’s theory (Srinivasan et al., 2007). However, more recent evidence 
suggests that several organ specific lymphatic vessels draw some lymphatic 
endothelial cells from local sources including those of the heart, the intestine 
and the skin (Klotz et al., 2015; Martinez-Corral et al., 2015; Stanczuk et al., 
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2015). Integrating these more-recent theories, the current model suggests 
that central cardinal vein derived lymphatics cooperate with local sources to 
form mature lymphatic vessel endothelium (Ulvmar and Makinen, 2016). A 
critical function of the lymphatic system is the anterograde movement of 
excess interstitial fluid from tissues back into the blood vascular system 
(Swartz, 2001). The lymphatic endothelium lining the lymphatic vessels is in 
continuity with the central venous system, yet the lymphatic vessels remain 
clear of blood, thus mechanisms preventing the back flow of blood, from high-
pressure blood vessels into the lower pressure lymphatic vessels, are 
operational. These findings raise a critical question: how is the separation of 
blood - lymphatic system established and maintained? 
 
Blood Lymph Separation 
The lymphatics are an open vascular system that carry excess extravasated  
interstitial fluid unidirectionally from peripheral tissues and return it to the 
blood vascular system at the bilateral lymphovenous junction (LVJ). The right 
LVJ interfaces with the right lymphatic duct at the right subclavian and jugular 
vein junction (Smith et al., 2013). The left LVJ interfaces with the thoracic duct 
at the junction created by the left subclavian and left jugular veins (Ratnayake 
et al., 2018). As it serves as the connection between lymphatic and blood 
vascular spaces, a critical physiological function of the LVJ is to prevent reflux 
of blood from the high-pressure blood vascular system into the low-pressure 
lymphatic vasculature.  
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Lymphovenous Junction in health and disease 
Florence Sabin, through detailed studies on human embryos in the 
early 20th century, revealed the structural and developmental anatomy of the 
human lymphovenous junction including the identification of a valve guarding 
the junction (Sabin, 1909). Subsequent studies in cadavers and surgical 
patients identified the common features and variations in terminal branches of 
thoracic duct and its interface with the central venous system (Davis, 1915; 
Kinnaert, 1973; Langford et al., 1999; Yalakurthi et al., 2013). The thoracic 
duct drains lymph fluid from the lower limbs, abdomen, pelvis, left thorax, 
head, and neck back into venous circulation. The right lymphatic duct drains 
lymph from the right thorax and right cervical regions (Smith et al., 2013). 
Approximately 87.5% humans have the thoracic duct with a single opening 
into the venous system, while the rest have 2 or more openings. In almost half 
of humans, the thoracic duct opens either into the left internal jugular vein or 
the venous angle at the of the left internal jugular vein and left subclavian 
veins. The thoracic duct drains lymph exclusively into the left lymphovenous 
junction in nearly 95% of humans (Ratnayake et al., 2018). Recent advances 
in imaging technologies, such as high-resolution ultrasonography, make it 
possible to image the terminal thoracic duct and motion of the lymphovenous 
valves (Seeger et al., 2009).  
The lymphovenous valve is composed of bicuspid leaflets that open 
obliquely into the central venous system such that one of the cusps is 
anatomically superior to the other (Shimada and Sato, 1997). At the 
lymphovenous junction, the thoracic duct is narrow with a thin endothelial 
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layer and a sub-endothelial layer composed of smooth muscle fibers, elastic 
and collagenous fibers. The internal elastic lamina has a thin, network like 
structure accompanied by two or three layers of longitudinally arranged 
smooth muscle.  The medial layer is composed of very few connective tissue 
or elastic fibers. Scanning electron microscopy showed thinner smooth 
muscle layer and fine connective tissue fibers near the lymphovenous 
junction. Immunostaining identified strong expression of extracellular matrix 
proteins, such as Collagen I, Collagen III, and Laminin within human 
lymphovenous valves (Shimada and Sato, 1997).  
Several factors control the anterograde movement of lymph from 
peripheral tissues to the LVJ including propulsive forces generated by 
contractions of smooth muscle surrounding collecting lymphatic vessels, 
passive body movements, pulsatile forces of adjacent blood vessel flow and 
respiratory cycle dynamics (Swartz, 2001). Measurement of thoracic duct 
pressure provides a functional assessment of the lymphovenous valves in 
humans. During inspiration, central venous pressure drops and venous wall 
relaxes, which in turn opens the lymphovenous valves allowing anterograde 
drainage of lymph from the thoracic duct into the venous system. In contrast, 
expiration increases central venous pressure, thus closing the lymphovenous 
valves (Calnan et al., 1970; Pelug and Calnan, 1968). However, pathologic 
increases in central venous pressure in conditions such as chronic renal 
failure and congestive heart failure, leads to failure of lymphovenous valve-
mediated blood/lymph segregation (Kochilas et al., 2014; Ratnayake et al., 
2018; Witte et al., 1969). Accordingly, patients with chronic renal failure show 
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blood in the thoracic duct (Kinnaert, 1973). Of note, physiological venous 
reflux into the thoracic duct has been observed in approximately 20% patients 
by CT scans (Kammerer et al., 2016; Liu et al., 2006; Seeger et al., 2009).  
Not withstanding the observations in the clinic, until recently, little progress 
was seen in understanding the molecular and cellular development of the 
LVJ. 
 
Lymphovenous valve development and function 
Human embryological studies by Sabin in the beginning of the 20th century 
described the embryonic LVJ (Sabin, 1909). Anterior jugular lymph sacs 
connect to jugular veins via an immature valve, thus enforcing blood/lymph 
segregation. Nearly a century later, with the discovery of molecular markers 
specific to the lymphatic system such as Prox1, more detailed anatomical 
studies of the lymphovenous junction were possible using the murine model 
system (Srinivasan et al., 2011). Immuno-staining for Prox1, a transcription 
factor critical for lymphatic system development, in serial sections of the 
murine embryos established that the lympho-venous segregation is 
maintained by the presence of pairs of symmetric Lympho-Venous Valves 
(LVVs) located bilaterally. On each side, one valve is situated dorso-medially 
relative to the other and is formed by the confluence between the jugular 
lymph sac, internal jugular veins, and external jugular veins. Its partner is 
formed by the junction between lymph sac, the superior vena cava, external 
jugular vein, and the subclavian vein (Srinivasan et al., 2011). The valve 
leaflets are made of two layers of endothelial cells: an outer layer of Lympho-
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Venous Valve Endothelial Cells (LVV-ECs) oriented towards the lumen of the 
superior vena cava, in continuity with the endothelial lining of the jugular or 
subclavian veins and an inner layer of Lymphatic Endothelial Cells (LECs) 
oriented towards the lumen of the lymph sac (Geng et al., 2016; Srinivasan et 
al., 2011). LVV-ECs are characterized by high expression of Prox1, Gata2, 
Foxc2, integrin-α9 and integrin-α5 and low expression of Vegfr3 and do not 
express Podoplanin or Lyve1 (Geng et al., 2016). In contrast, LECs express a 
comparatively reduced level of Prox1, Gata2 and Foxc2 but express lymphatic 
markers such as Vegfr3, Lyve1 and Podoplanin (Geng et al., 2016).  
Murine LVV development is orchestrated in a step-wise manner 
beginning with specification of LVV-ECs from venous endothelial cells at 
embryonic day 12 after fertilization. In the next 12-hours following 
specification, invagination of LECs and LVV-ECs into the venous lumen forms 
an immature valve-like structure. Finally, from embryonic day 14.5 till birth, the 
immature valve develops, characterized by endothelial cell elongation, 
extracellular matrix deposition and recruitment of mural cells including 
pericytes and smooth muscle cells to the valve leaflets (Geng et al., 2016).  
Murine genetic models continue to be a valuable resource for 
elucidating the molecular basis of lymphatic development. Several mouse 
models with targeted deficiencies for specific proteins including Prox1, Foxc2, 
Cx37, Gata2, CYP26B1, EphB4, beta catenin, integrin-α5 (ITGA5), display 
defective LVV formation at various stages of development (Bowles et al., 
2014; Cha et al., 2016; Turner et al., 2014; Geng et al., 2016; Kazenwadel et 
al., 2015; Martin-Almedina et al., 2016; Srinivasan et al., 2011). For instance, 
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mice with reduced expression of Prox1 (Prox1+/-) do not properly specify LLV-
ECs and consequently do not form LVVs (Srinivasan et al., 2011). Instead, 
the jugular lymph sacs in Prox1+/- mice were shown to make abnormal 
connections with the central veins as a consequence of increase fluid 
pressure within the lymph sac. Furthermore, a small fraction of the embryos 
displayed peripheral blood filled lymphatic vessels possibly due to back flow 
of blood from the high-pressure venous vessels to low-pressure lymphatic 
vessels. This body of work suggests that Prox1 not only marks the presence 
of lymphovenous valves but also is required for their formation and 
maintenance (Srinivasan et al., 2011).  
GATA2 is a zinc-finger transcription factor mutated in patients 
presenting with primary lymphedema (Kazenwadel et al., 2012; Ostergaard et 
al., 2011). Analysis of mice genetically deficient for endothelial Gata2 show 
multilayered, poorly organized LVV leaflets and consequent defective blood 
lymph separation. Interestingly, Prox1 expression is significantly reduced in 
the Gata2-null LVV-ECs possibly resulting in loss of LVV-EC identity in the 
developing LVV leaflets	(Geng et al., 2016; Kazenwadel et al., 2015). 
FOXC2 is a transcription factor that is frequently mutated in patients 
with lymphedema-distichiasis (Fang et al., 2000). Mice with deletion for Foxc2 
have immature collecting vessels lacking lymphatic valves, recapitulating 
human disease (Petrova et al., 2004). Foxc2- heterozygous and homozygous 
knockout mice revealed reduced number or complete absence of LVVs, 
respectively (Geng et al., 2016). Interestingly, the number of LVVs negatively 
correlates with the presence of embryonic edema. Mechanistically, loss of 
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Foxc2 leads to defective specification of LVV-ECs (Geng et al., 2016). Foxc2 
transcriptionally regulates Cx37, a gap junction protein required for LECs to 
function in a coordinated manner (Sabine et al., 2012). Although specification 
of LVV-ECs is not perturbed in mice lacking Cx37, the cells fail to form 
functional valve leaflets due to a failure of normal invagination (Geng et al., 
2016).  
CYP26B1, a cytochrome P450 enzyme, catalyzes the breakdown of 
Retinoic Acid (RA). Global loss of Cyp26b1 in mice results in excess 
activation of RA signaling within the developing lymphatic system leading to 
loss of polarized Prox1 expression within the cardinal vein and excessive 
specification/proliferation of LEC progenitor cells. Mice lacking Cyp26b1 
display enlarged blood filled lymph sacs with abnormal LVV leaflets 
composed of increased number of Prox1+ cells (Bowles et al., 2014).  
Hydrops fetalis is a disorder characterized by fluid accumulation in the 
fetus. As a major regulator of tissue fluid balance, lymphatic system 
dysfunction is implicated in nearly 15% of non-immune-related cases of 
hydrops fetalis (Bellini et al., 2015). A recent study of two families with a 
history of non-immune hydrops found mutations in the endothelial tyrosine 
kinase EphB4 (Martin-Almedina et al., 2016). Mice with targeted deletion of 
EphB4 within lymphatic endothelial cells showed defective LVV development 
characterized by shortened valve leaflets and abnormal clustering of Prox1 
positive cells at the LV Junction (Martin-Almedina et al., 2016). Kinase 
inactive EphB4 mutant mice show defective collecting vessel lymphatic valve 
development but whether the kinase activity of EphB4 is required for normal 
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LVV development remains to be defined (Zhang et al., 2015). Other mutations 
identified in cases of non-immune related hydrops fetalis include CCBE1, 
FAT4 and PEIZO1, however their requirement for LVV development is not 
known (Alders et al., 2014; 2009; Fotiou et al., 2015; Shah et al., 2013).  
Finally, another developmentally active pathway demonstrated to be 
required for LVV development is the Wnt-beta catenin signaling pathway. 
Mice with targeted deletion of Ctnnb1, encoding beta-catenin, within LECs, 
have no LVV valves and a complete absence of LVV-EC differentiation (Cha 
et al., 2016).  
 
Platelet mediated Inter-vascular Hemostasis 
        In addition to the presence of LVVs, platelet mediated physiological 
hemostasis at the LV junction prevents backflow of venous blood into the 
lymphatic circulation, thus establishing and maintaining lifelong blood lymph 
separation (Hess et al., 2013). In contrast to platelet mediated hemostasis 
that occurs after endothelial cell injury in blood vessels, LVJ hemostasis 
involves interaction of platelets with uninjured lymphatic endothelial cells at 
the LV junction. This interaction activates platelets resulting in a platelet plug 
and thrombus formation (Welsh et al., 2016). This phenomenon was first 
detected in mice deficient in immune receptor activated platelet signaling 
proteins Slp-76 and Syk (Abtahian et al., 2003). Slp-76 deficient mice 
presented with partial perinatal lethality; surviving mice showed chylous 
peritoneal hemorrhage suggesting involvement of lymphatic system. 
Irradiated wild-type mice transplanted with Slp-76 deficient hematopoietic 
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cells recapitulated the phenotype of Slp-76 knockout mice suggesting that 
Slp-76 and Syk were required within hematopoietic cells and not in endothelial 
cells for blood lymph separation (Abtahian et al., 2003).  
Analyses of how hematopoietic cells regulate the separation of the two 
vascular systems revealed Clec2, a platelet cell surface receptor, functions 
upstream of Slp-76 and Syk (Suzuki-Inoue, 2006). A subsequent study 
identified Podoplanin, an O-glycosylated protein expressed on the surface of 
LECs, as a ligand for Clec2 (Suzuki-Inoue et al., 2007). Mechanistically, the 
interaction between Podoplanin and Clec2 robustly induced platelet 
aggregation in a Syk, Slp-76 and Plcγ dependent manner (Suzuki-Inoue et al., 
2007). Accordingly, interfering with platelet aggregation through injecting 
pregnant mice with anti-podoplanin antibody, treatment of mice with acetyl 
salicylic acid, or mice deficient in Kindlin3 (a platelet integrin) resulted in 
defective blood lymph separation (Uhrin et al., 2010).  
Consistent with these observations, Podoplanin knockout mice exhibit 
aberrant presence of blood within intestinal lymphatics (Bertozzi et al., 2010; 
Uhrin et al., 2010). In addition, conditional deficiency of O-glycan synthase, 
the enzyme required for o-glycosylation of Podoplanin in hematopoietic and 
endothelial cells, resulted in intestinal blood lymph mixing and reduced 
expression of Podoplanin (Fu et al., 2008). In contrast to the hematopoietic 
requirement for Syk and Slp-76, bone marrow transplant experiments with 
reconstitution of O-glycan synthase deficient hematopoietic cells, did not 
display the blood lymph separation phenotype indicating that Podoplanin is 
required in a non-hematopoietic cell type (Fu et al., 2008). Interestingly, 
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Podoplanin-null mice exhibit variable survival and surviving mice show 
complete blood-lymph separation at postnatal stages suggesting additional 
ligands of Clec2 in LECs (Suzuki-Inoue et al., 2010; Uhrin et al., 2010). 
However, a more recent study determined that Podoplanin is essential 
throughout postnatal life to maintain blood lymph separation (Bianchi et al., 
2017).  
Animal studies established the in vivo requirement of hematopoietic 
Clec2 in blood lymph separation and normal lymphatic development. 
Irradiated wildtype mice reconstituted with hematopoietic cells lacking Clec2 
exhibit defective blood-lymph separation. Consistent with this observation, 
Bertozzi et al demonstrated that megakaryocyte or platelet Clec2 is critical for 
maintenance of blood lymph separation (Bertozzi et al., 2010). However, 
Clec2 function in other hematopoietic lineages, including neutrophils and 
macrophages, is dispensable (Finney et al., 2012).  
The exact location of platelet Clec2-LEC-Podoplanin interaction, after 
careful analysis of histology and staining for platelet aggregates and 
thrombus, was found by Uhrin et al to be at the developing LVJ. They found 
that Clec2-Podoplanin interaction at the developing LVJ resulted in platelet 
aggregation in wildtype embryos but that this aggregation was lost in 
Podoplanin-null embryos (Uhrin et al., 2010). In addition, Hess et al 
determined that even through late gestation, the LV junction continues to 
remain the only site where platelets aggregate. In this model, treatment with 
an anti-Clec2 antibody in wildtype mice rapidly causes a failure of blood/lymph 
segregation, resulting in blood filled intestinal lymphatics (Hess et al., 2013). A 
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careful analysis of phenotype development revealed that blood flowed into the 
lymphatics in a retrograde fashion from the thoracic duct, through the 
mesenteric lymph nodes into the mesenteric collecting lymphatic vessels and 
finally into the intestinal lymphatics. This suggested that the point of 
interaction between platelets and endothelial cells was away from the 
intestine. Importantly, blood filled lymphatics also developed in LTA-/- and 
RORC-/- mice (characterized by a lack of lymph nodes) suggesting that the 
site of platelet-LEC interaction is not in the lymph node (Hess et al., 2013). 
Syk inhibitor treated mice exhibit complete blood lymph separation, 
suggesting that even minor amounts of preserved platelet signaling can 
maintain blood-lymph separation (Hess et al., 2013).  
Finally, as platelet mediated thrombus formation is the key endpoint of 
Podoplanin-Clec2 signaling, the studies provide further evidence for a 
hemostatic mechanism of blood-lymphatic separation. Together these findings 
highlight the critical in vivo role of Podoplanin–Clec2 interaction and the 
importance of platelet aggregation in effecting blood lymph separation.  
These results raise an interesting question: How does establishment of 
a thrombus at the LVJ prevent back flow of venous blood yet allows the 
simultaneous unimpeded anterograde lymph flow? Recent work from the 
Griffin laboratory demonstrates that Chd4, a component of the NuRD 
chromatin repressive complex, is required for establishment of blood lymph 
separation in mice (Crosswhite et al., 2016). LEC-specific ablation of Chd4 in 
mice causes robust expression of Plasminogen activator uPA, activating 
plasmin, an anticoagulant enzyme; and leading to dissolution of the thrombus 
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at the jugular lymph sac. Genetic deletion of uPA rescued both thrombus 
formation and blood-lymph separation defect in Chd4-null mice, however the 
genetically rescued pups were not recovered at birth suggesting uPA 
independent increase of plasmin activity (Crosswhite et al., 2016). Currently 
three models have been proposed to explain how the LVJ could both maintain 
forward lymph drainage and prevent blood reflux (Welsh et al., 2016). First, in 
a dynamic lymphovenous clot model, thrombi at the LVJ block retrograde 
blood flow while sustaining increasing pressure within the jugular lymph 
sac/thoracic duct. Increase in lymphatic pressure beyond a threshold 
dislodges the thrombus allowing transient anterograde lymph flow (Welsh et 
al., 2016). Because of the existence of multiple LVJ’s, in the second ‘pressure 
mediated dormant valve model’, some junctions allow anterograde lymph flow 
while others prevent retrograde venous blood flow (Welsh et al., 2016). 
Finally, in the lymph fluid lysis model, forward lymph flow occurs when lymph 
fluid, normally enriched for clot lysis factors, is in proximity to the LVJ allowing 
the dissolution of the clot. In contrast when venous blood comes in contact 
with the LVJ, a clot is formed preventing retrograde flow of blood into the 
lymphatic system (Welsh et al., 2016). 
              Finally, Clec2 deficient mice exhibit a normally sized and structured 
LVV in absence of platelet-LEC interaction and thrombus formation (Hess et 
al., 2013). Whether a defective LVV or defective lymphatic valves affect LV 
hemostasis was addressed by examining the lymphatics in embryos with 
absent LVVs (Prox1+/-) and those with absent lymphatic valves (Itga9-/-). 
Both Prox1+/- mice and Itga9-/- embryos had more extensive thrombus 
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formation in the thoracic duct and only some Prox1+/- embryos had blood-
filled dermal lymphatic vessels suggesting compensation by platelets. The 
fact that some Prox1+/- embryos presented with blood-filled dermal 
lymphatics, we can infer that the LVV is required for segregation of blood and 
lymphatic systems (Hess et al., 2013). In conclusion, both platelet-mediated 
lymphovenous hemostasis together with LVVs effect complete blood lymph 
separation. 
 
Lymphatic Valve Development 
In addition to the lymphovenous valves that guard the lymphovenous 
junction, the lymphatic vascular system also contain bicuspid valves within 
peripheral collecting vessels which mediate the unidirectional anterograde 
flow of lymph from capillary beds to the thoracic duct. Insights into the 
molecular regulation of lymphatic valve development were first derived from 
studies modeling the human syndrome Lymphedema Distichiasis in mice 
(Petrova et al., 2004). Loss of Foxc2 in these mice resulted in complete 
agenesis of lymphatic valves. Analysis of Foxc2 chromatin binding sites in 
LECs identified enrichment for Nfatc1 binding sites, suggesting cooperation 
between Foxc2 and Nfatc1 in regulating lymphatic development (Norrmén et 
al., 2009). Indeed, genetic studies using heterozygous Foxc2 treated with the 
calcineurin signaling inhibitor CsA exhibit loss of nuclear Nfatc1 and valve 
agenesis (Sabine et al., 2012). The cell autonomous requirement for Nfatc1 in 
lymphatic valve formation and maintenance was further confirmed by 
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inactivating the regulatory subunit of calcineurin (Cnb1) in LECs in mice 
(Sabine et al., 2012).  
Based on morphological and molecular analysis, mesenteric collecting 
vessel lymphatic valve formation occurs in four distinct developmental stages: 
initiation, condensation, elongation, and maturation. In murine embryos, 
initiation of valve formation starts around embryonic day 16 and is marked by 
the presence of LECs with increased expression of Prox1 (Prox1high) and 
Foxc2. The cells then condense into a ring like state accompanied by 
polarized but contrasting expression of Prox1 and Foxc2 upstream and 
downstream of the future valve. In stage 3, the cell reorientation and 
invagination into the vessel lumen is accompanied by deposition of 
extracellular matrix proteins such as laminin alpha 5. Finally, the valve 
matures with the deposition of a thickened matrix core (Sabine et al., 2012).  
The highly regulated orientation of the valve forming LECs during 
lymphatic valve development suggests coordination between these LECs, 
likely via gap junction proteins. Indeed, mice lacking gap junction proteins, 
Cx37 and Cx43 display immature lymphatic valves (Kanady et al., 2011). 
Furthermore, mice heterozygous for Foxc2 and Cx37 have decreased 
numbers of mature valves, suggesting a genetic interaction between 
transcription factors and gap junction proteins (Kanady et al., 2015). 
Further insights into the process of valve development were derived 
from the observations that flow within the mesenteric lymphatic system is 
initiated about 12 hours prior to the onset of valve forming regions, in between 
lymphangions, and valves are more frequently found near areas of disturbed 
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flow such as vessel bifurcations. Remarkably, mimicking in vivo flow 
conditions by subjecting cultured LECs to oscillatory shear stress (OSS) 
resulted in similar morphological and molecular changes in LECs including 
increased Foxc2, Gata2, and Cx37 expression (Kazenwadel et al., 2015). 
Experiments from Kahn lab further supported the role of lymph flow in 
initiating valve formation (Sweet et al., 2015). Sweet et al demonstrated that 
Clec2 deficient embryos exhibit blood filled lymphatics resulting in blockade of 
anterograde lymphatic flow. These mice displayed reduced number of 
lymphatic valves and decreased expression of Foxc2 and Cx37.  
Patients presenting with hereditary lymphedema, associated with Emberger 
and MonoMac syndromes, revealed another key zinc finger transcription 
factor, Gata2, in lymphatic valve development (Hsu et al., 2013; Kazenwadel 
et al., 2012; Ostergaard et al., 2011). Gata2 is expressed in all lymphatic 
vessels with higher expression in lymphatic valves (Kazenwadel et al., 2012; 
2015). Knockdown of Gata2 in cultured LECs resulted in reduced expression 
of Foxc2, Cx37, Itga9, and Prox1 suggesting Gata2 is an upstream regulator 
of key genes in valve development. Furthermore, Gata2 has been shown to 
directly bind enhancers regulating Foxc2 and Prox1 (Kazenwadel et al., 
2015). Indeed, mice lacking Gata2 within lymphatic endothelial cells exhibit 
significantly reduced number of lymphatic valves, suggesting that Gata2 is a 
critical regulator of lymphatic valve development (Kazenwadel et al., 2015). 
Despite this evidence, the exact molecular pathways that translate shear 
stress signals to downstream transcriptional changes in genes critical for 
lymphatic valve formation are not well understood. 
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Recently, the Wnt/β-catenin signaling pathway has been shown to be 
active in developing lymphatic valves with deletion of β-catenin in lymphatic 
endothelial cells in mice arresting valve initiation (Cha et al., 2016). Follow up 
in vitro experiments suggested that β-catenin directly binds to upstream 
regulatory elements of Foxc2 and Prox1 to regulate their expression. Despite 
the interaction, genetic expression of Foxc2 in β-catenin-null mice failed to 
rescue lymphatic valve formation suggesting the involvement of other targets 
(Cha et al., 2016).  
The identification of a blood endothelial cell shear stress 
mechanosensory complex composed of endothelial membrane proteins 
Vegfr2, Vegfr3, Pecam1, and Cdh5; and another endothelial transmembrane 
proteoglycan, Syndecan-4 in regulating endothelial alignment to flow suggests 
the possibility of similar complexes or proteins playing a role in lymphatic 
endothelial cells (Baeyens et al., 2014; Coon et al., 2015; Tzima et al., 2005). 
A recent study evaluated whether Pecam1 and Syndecan-4 could mediate 
shear stress responsiveness of LECs (Wang et al., 2016).  Analysis of 
mesenteric lymphatic collecting vessels revealed that Pecam1 deficient mice 
and Syndecan-4 deficient mice failed to form mature valves. Instead the valve 
forming regions were occupied by disoriented Prox1high valve forming LECs, 
suggesting a functional relationship between the lymphatic mechanosensory 
complex and planar cell polarity (Wang et al., 2016). Indeed, knockdown of 
Syndecan-4 causes increased expression of Vangl2, a component of planar 
cell polarity signaling, and misalignment of cultured LECs in response to 
laminar flow. Simultaneous knockdown of Syndecan-4 and Vangl2 restored 
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flow-mediated LEC orientation (Wang et al., 2016). Consistent with this, mice 
lacking planar cell polarity signaling components, Vangl2 or Celsr1, show 
disoriented Prox1high valve forming LECs, indicating defective lymphatic valve 
development (Tatin et al., 2013). Patients with mutations in genes regulating 
planer cell polarity, such as FAT4 and CESLR show lymphedema (Alders et 
al., 2014; M L Gonzalez-Garay, 2016). Loss of Fat4 in mice cause decreased 
percent of lymphatic valve formation, however, initiation of Prox1 expressing 
clusters remains unaltered (Pujol et al., 2017). 
Interestingly, Syndecan-4 has been shown to play a role in regulating 
the activity of several signaling pathways including Calcineurin/NFAT 
signaling, Wnt-b catenin signaling and Wnt/Planar cell polarity pathway that 
have been implicated in lymphatic valve development as noted above. For 
examples, activation of Calcineurin/NFAT signaling in response to mechanical 
stretching of cardiomyocytes is dependent on Syndecan-4; and a genetic 
interaction between Vangl2 and Syndecan-4 has been shown to orchestrate 
spinal neural tube closure and orientation of stereocilia bundles in cochlea of 
mice (Escobedo et al., 2013; Finsen et al., 2011). 
Tie1, a receptor tyrosine kinase has been implicated in shear stress 
dependent initiation and maintenance of atherosclerotic plaques, positioning it 
a LEC mechanotransducer candidate (Woo et al., 2011). Indeed, lymphatic 
specific Tie1 ablation in mice causes mesenteric lymphatic valvular agenesis 
and a dramatic reduction in the number of Prox1high expressing valve clusters 
(Qu et al., 2015).   
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Several other developmentally active signaling pathways, such as 
Bone morphogenic protein (Bmp), Notch, Semaphorin, Plexin, and Ephrin, 
have been shown to regulate murine lymphatic valve development (Bouvrée 
et al., 2012; Jurisic et al., 2012; Levet et al., 2013; Murtomaki et al., 2014; 
Mäkinen et al., 2005; Zhang et al., 2015). For instance, Notch1 expression 
and activity are enriched in developing lymphatic valves suggested a role for 
the Notch pathway in lymphatic valvulogenesis. Indeed, Prox1high LECs failed 
to cluster and reorient to form valves in mice lacking Notch1 or expressing a 
dominant negative regulator of MAML, a component of the Notch signaling 
pathway (Murtomaki et al., 2014). In addition, Notch expression in cultured 
LECs induced the expression of Itga9, Fibronectin EIIIA, and Cx37, proteins 
critical for lymphatic valve maturation (Murtomaki et al., 2014).  
Analysis of the transcriptome profile of LECs isolated from mouse 
colonic tissue revealed an unexpected enrichment for axonal guidance 
proteins Sema3A and Sema3D (Jurisic et al., 2012). Nrp1, a receptor for 
Semaphorin ligands, is expressed by smooth muscle cells surrounding the 
lymphatic collecting vessel and also in lymphatic valve leaflets. Injection of 
Nrp1 antibodies into mice resulted in increased pericyte coverage of collecting 
lymphatics. Interestingly, quantification of valve number revealed no 
significant differences, yet the expression of Itga9 appeared mislocalized and 
distribution of fibronectin EIIIA appeared diffuse in these mice (Jurisic et al., 
2012). In a parallel independent study, mice deficient in Sema3a or either the 
Sema3a-receptors Nrp1 or PlexinA1, resulted in formation of smaller 
lymphatic valves with excessive smooth muscle cell coverage (Bouvrée et al., 
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2012). Ephrin B2-EphB4 signaling is also required for lymphatic valve 
development. Mice with homozygous deletion of a C-terminus valine residue 
in the PDZ interaction domain of Ephrin B2 or loss of EphB4 completely lack 
of mesenteric lymphatic valves (Mäkinen et al., 2005). An independent study 
revealed that tyrosine kinase activity of EphrinB2 receptor, EphB4, is required 
for lymphatic valve development and maintenance (Zhang et al., 2015).  
Bmp9 signaling is required for lymphatic valve development. Bmp9 KO 
mice have reduced number of mesenteric collecting vessel valves with 
defective initiation and maturation (Levet et al., 2013). Addition of Bmp9 to 
cultured LECs increased Foxc2 and Cx37 expression in an Alk1 receptor 
dependent manner (Levet et al., 2013).  
Finally, maturation of lymphatic valves is associated with deposition of 
a core matrix of extracellular matrix proteins that provides structural integrity 
allowing the valve to weather constant shear stress.  LEC-integrin and 
extracellular matrix interactions are critical for lymphatic valve function in 
humans and mice. For instance, mutations in Itga9 have been found in 
fetuses presenting with bilateral chylothorax (Ma et al., 2008). Consistent with 
this, mice lacking Itga9 display defective lymphatic valves and die postnatally 
due to bilateral chylothorax (Bazigou et al., 2009). Itga9 binds multiple ECM 
ligands including Emilin1, Fibronectin EIIIA, Osteopontin, and Tenascin C, 
however; only Emilin1 and Fibronectin EIIIA have so far been shown to be 
important for valve maturation (Carla Danussi, 2008; Bazigou et al., 2009). 
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Histone acetylation/deacetylation and transcription  
Embryonic development is a complex process characterized by the 
generation of multiple cell types which organize to form tissues, organs and 
organ systems. Precise coordination of gene expression in a spatiotemporal 
manner is critical for expression of unique cellular programs, and plays an 
integral role in all developmental processes. Alterations in global and local 
chromatin architecture work in concert to orchestrate and regulate gene 
expression (Perino and Veenstra, 2016). The basic structural unit of 
chromatin is made up of 146 base pairs of DNA wound around an octamer 
core of 2 subunits each of basic proteins, the histones H2A, H2B, H3 and H4 
(Luger et al., 1997). Chemical modifications of histones, such as acetylation, 
methylation, and phosphorylation can modulate compaction of DNA or serve 
as docking sites for other proteins, thereby regulating transcription (Bannister 
and Kouzarides, 2011). For example, acetylation of H3 at lysine 56 
(H3K56ac), located at a part where the DNA enters and exits the nucleosome, 
results in opening of surrounding DNA sequences, allowing binding of 
transcription factors and the progression of RNA polymerase (Marushige, 
1976; Xu et al., 2005).  
Histone acetyl transferases (HATs), a group of histone-modifying 
enzymes, catalyze the addition of acetyl group to generate ε-N-acetyl lysine 
residues in histones (Roth et al., 2001). These enzymes lack DNA binding 
domains and are recruited to the chromatin as part of multi-protein complexes 
(Lee and Workman, 2007). For example, the HAT Gcn5, part of the SAGA 
and SLIK complexes, acetylates histones H3 and H2B (Suka et al., 2001). 
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Similarly, chromodomain proteins, which bind to methylated histones, recruit 
HATs specifically to H3 lysine 4 methylation in promoters and H3 lysine 36 
methylation sites in gene bodies (Cavalli and Paro, 1998). Bromodomain 
containing HATs not only acetylate histone lysines, but also directly bind to 
already acetylated lysine residues, and maintain their presence at the loci 
(Fujisawa and Filippakopoulos, 2017). Overall, HATs facilitate transcription of 
genes through a series of coordinated steps starting with recruitment to 
specific loci by transcription factors, subsequent acetylation of lysine residues, 
opening of local chromatin, and further recruitment of factors and other 
chromatin remodeling complexes (Shahbazian and Grunstein, 2007).  
Opposing HATs, Histone deacetylases (HDACs) are an evolutionarily 
conserved group of histone modifying enzymes that catalyze the removal of 
acetyl groups from ε-N acetyl lysine residues in histone and non-histone 
proteins. Broadly, mammalian HDACs are divided into four classes including 
the Classes I, II, III (NAD+ dependent deacetylases, Sirtuins) and IV 
(Haberland et al., 2009b). The majority of nuclear histone deacetylation is 
mediated by class I deacetylases, Hdac1, 2, 3 and 8, defined by their 
homology to yeast deacetylase Rpd3. Class II Hdacs, defined by homology to 
yeast deacetylase Hda1 are subdivided into 2 groups, IIa (Hdacs 4, 5, 7, 9) 
and IIb (Hdacs 6, 10). Class II Hdacs are signal responsive and shuttle 
between the cytoplasm and nucleus. In addition, Class II Hdacs possess 
weak intrinsic deacetylase activity and depend on Class I Hdacs for their 
nuclear deacetylase function (Fischle et al., 2002). Hdac11 is the sole 
deacetylase within Class IV and contains a conserved core catalytic domain 
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similar to Class I and II Hdacs (Gao et al., 2002). Studies in yeast have 
determined that Rpd3 acts on all 4 histones while Hda1 acts only on H3 and 
H2B. Like HATs, HDACs function as a part of multi-protein complexes and are 
thus recruited to site-specific loci by transcription factors or cofactors (Jepsen 
and Rosenfeld, 2002). For example, Hdac1 and Hdac2 are a part of the 
NuRD, CoREST and Sin3a complexes while Hdac3 associated with NCoR 
and SMRT.  
In addition to deacetylation and chromatin compaction, HDACs permit 
recruitment of factors to unacetylated histones. For instance, the SANT 
domain containing repressor complexes, such as NCoR, SMRT, and 
CoREST, bind deacetylated H4 lysine 5. SMRT has 2 SANT domains, one 
binds to Hdac3 and the other binds to H4 lysine 5. Hdac3 in turn deacetylates 
H4 lysine 5 resulting in a self-propogating loop of Hdac3 recruitment (Yu, 
2003). In addition to recruiting histone-modifying enzymes, SANT domain 
containing proteins can also recruit chromatin-remodeling complexes both for 
repression and activation (Boyer et al., 2004).  
Although HDACs have been traditionally associated with transcriptional 
repression; recent chromatin-binding profiles for HDACs exhibit a robust 
presence at actively transcribed regions of the genome (Wang et al., 2009). 
There is also evidence for recruitment of both HATs and HDACs by common 
interacting factors to active genes. For example EAF3, a chromodomain 
containing protein that binds to methylated H3 lysine 56, is part of both the 
NuA4 HAT complex and also a complex with Rpd3c (HDAC homologue) (Sun 
et al., 2008). While there is no conclusive model, HDAC recruitment at active 
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genes could function to prepare for rapid repression following stimuli induced 
activation. For example, in response to growth factor stimuli transcription 
factor Elk3 recruits Hdac1 to the c-Fos gene. This recruitment is required for 
rapid abatement of c-Fos transcriptional activation (Yang et al., 2001). 
Simultaneous recruitment of HDACs along with HATs could also serve to limit 
the amount of transcriptional activation in response to stimuli. Presence of 
HDACs at active genes could also promote transcription. Supporting this, rate 
of histone acetylation turnover appears to be correlated with transcription. For 
instance, Hos2 deacetylase is required for induction of Gal1 gene. Loss of 
Hos2 results in hyper-acetylation of H3 and H4, which in turn, leads to failed 
induction of Gal1 (Wang, 2002). Using fluorescence resonance energy 
transfer analysis, HDACs and HATs have been observed to exist in close 
proximity within cells such that they physically interact (Yamagoe et al., 2003). 
Such an association has been proposed to facilitate rapid turnover of 
acetylation and increased transcription (Yamagoe et al., 2003). More recently, 
Hdac3 has been shown to interact and recruit p300, a histone 
acetyltransferase; to target genes for activation in a deacetylase-independent 
fashion, suggesting broader mechanisms by which HDACs control gene 
transcription (Zhang et al., 2016). 
 
HDACs in vascular development and disease 
Recent evidences from our laboratory and others suggest tissue-
specific and spatiotemporal functions of HDACs during development 
(Goldfarb et al., 2016; Lewandowski et al., 2014; 2015). Although substantial 
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progress has been made in understanding the role of class I HDACs in 
cardiac development and beyond, their functions in vascular development 
remain unknown. Initial interest in endothelial function of HDACs developed 
because of the potential utility of HDAC inhibitors in cancer therapy. Studies 
suggest that Trichostatin A (TSA), a pan-HDAC inhibitor, inhibits hypoxia 
induced VEGF expression in cultured tumor cells (Williams, 2005). 
Subsequent studies have shown that HDACs may regulate the proliferation, 
migration, apoptosis and differentiation of cultured endothelial cells (Zhou et 
al., 2011). For instance, loss of Hdac3 in ex vivo cultured aortic segments 
leads to endothelial cell apoptosis. In cultured endothelial cells Hdac3 forms a 
complex with AKT and increases its kinase activity leading to an endothelial 
pro-survival function in response to shear stress (Zampetaki et al., 2010). 
Among Class II HDACs, Hdac5 modulates migration and sprouting of 
endothelial cells through its regulation of Fgf2 expression in a deacetylase-
independent manner (Urbich et al., 2009). Similarly, Hdac6 deacetylates 
cortactin, a cytoplasmic protein, to control endothelial cell migration and 
sprout formation (Kaluza et al., 2011). Consistent with this finding Tubacin, a 
Hdac6 inhibitor, decreased tube formation and sprouting in cultured 
endothelial cells.  
Hdac7, a class II HDAC, is specifically expressed in endothelial cells 
during early murine development. Using tissue-specific mouse model, Hdac7 
has been shown to maintain vascular integrity by repressing the expression of 
matrix metalloproteinase, an enzyme that degrades the extracellular matrix 
(Chang et al., 2006). Hdac7 function can be regulated by phosphorylation 
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mediated by PLCγ/PKC/PKD pathway in response to VEGF leading to 
decreased tube formation ability of endothelial progenitor cells (Margariti et 
al., 2010). Despite this progress, there is a relative lack of understanding of 
the vivo function of class I HDACs during embryonic and postnatal vascular 
development. 
Conditional inactivation of genes in vascular endothelium 
	
Deciphering the molecular regulation of embryonic vascular development and 
postnatal vessel homeostasis requires inactivation of genes in a temporal and 
cell type specific manner within the endothelium. Over the last two decades 
murine studies have increasingly utilized the Cre/LoxP system to conditionally 
inactivate genes in various tissues. Cre/LoxP system involves the catalytic 
action of bacteriophage P1 - derived recombinase (Cre) on an identical pair of 
LoxP sites, similarly oriented 34bp DNA sequences. The LoxP sites flank an 
intervening DNA sequence within the gene targeted for inactivation. In vivo 
expression of Cre, under the control of a cell type specific promoter, results in 
recombination of the LoxP sites and permanent removal of the intervening 
DNA sequence from the host cell and its lineage. Breeding of transgenic mice 
lines that express Cre under the control of specific promoters with those that 
contain the floxed gene results in conditional gene inactivation in a tissue 
specific and spatiotemporal manner. Constitutively active Cre transgenic mice 
used in the study of gene function in blood endothelial cells or lymphatic 
endothelial cells include Tek-Cre, Cdh5-Cre, and Lyve1-Cre (Kisanuki et al., 
2001; Alva et al., 2006; Pham et al., 2010). Tek-Cre mice contain a transgene 
expressing Cre under the control of Tek promoter and enhancer elements 
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(Kisanuki et al., 2001). During embryonic development, Tek-Cre; as 
determined using a beta-galactosidase reporter, is expressed as early as 
embryonic day 8.5 (E8.5) and E9.5 in majority of vascular endothelial cells of 
the yolk sac and embryo respectively (Kisanuki et al., 2001). Although initial 
studies did not detect Tek-Cre activity in hematopoietic cells, subsequent 
studies by Tang et al determined that a majority of primitive hematopoietic 
cells in the yolk sac, primitive erythroid cells and adult hematopoietic cells 
including those from the bone marrow and spleen are of Tek-Cre lineage 
(Tang Y et al., 2010). To limit expression of Cre to endothelial cells, Alva et al 
used an alternate endothelial gene promoter to drive Cre recombinase in 
endothelial cells, Cdh5-Cre. Approximately 2.5Kb fragment of DNA sequence 
upstream of the translational start site of Cdh5 spliced to the gene encoding 
Cre was used for generating Cdh5-Cre transgenic mice (Alva et al., 2006). In 
contrast to Tek-Cre mice, Cdh5-Cre shows patchy activity in endothelial cells 
of embryonic vasculature at e8.5 and e9.5. However, by e14.5 nearly 96% of 
endothelial cells show Cre activity. Further, analysis of various hematopoietic 
organs such as the fetal liver, bone marrow, thymus and spleen together with 
circulating blood cells showed that nearly 50% of the cells were positive for 
Cre activity. In addition to blood endothelial cells, Cdh5-Cre activity is also 
noted in embryonic lymphatic vessels as early as e12.5 (Alva et al., 2006). To 
dissociate the requirement of gene function in blood endothelial cells versus 
lymphatic endothelial cells, transgenic mice that express Cre specifically in 
LECs have been developed. Lyve1-Cre mice express Cre under the control of 
promoter of Lyve1, a membrane protein expressed in LECs (Pham et al., 
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2010). Cre activity is noted as early as e9.5 in the cardinal vein prior to the 
development of first embryonic lymphatic structures, the lymph sacs. In 
addition to Cre expression in majority of the LECs, activity of Cre is also noted 
in Yolk sac blood vessels, vitelline blood vessels, sinusoidal endothelial cells 
of the liver and patchy expression in the endocardium, dorsal aorta and inter-
somitic blood vessels (Pham et al., 2010). Similar to other endothelial specific 
Cre transgenic mice, Lyve1-Cre activity is also noted in a fraction of CD45+ 
hematopoietic cells of the fetal liver including lymphocytes and myeloid cells. 
Further, about 35-40% of adult hematopoietic stem and progenitor cells are of 
Lyve1-Cre lineage (Lee et al., 2010). 				
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Aim of this work 
Class I Histone deacetylases comprising Hdacs 1, 2, 3 and 8, function 
primarily in the nucleus and account for the majority of cellular histone 
deacetylase activity. Germline loss of any Class I Histone deacetylase results 
in embryonic or perinatal lethality. The role of Class I Histone deacetylases in 
cardiac development has been investigated, however their roles in vascular 
development are unknown. The work presented here aims to advance the 
understanding of the role of Hdacs 1, 2 and 3 in vascular development. The 
findings presented here reveal that endothelial Histone deacetylase 3 
(Hdac3), not Hdac1 or Hdac2, is critical for lymphatic vascular development. 
Further, the findings presented provide novel insights into the role of Hdac3 in 
orchestrating the coordination between cell extrinsic and intrinsic cues to 
regulate lymphatic valve development. 
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Chapter II: Hdac3 regulates lymphovenous and lymphatic valve formation  
Chapter II is adapted from a published manuscript to include supplemental 
data and is included with permission not required. The term ‘enhanceosome’ 
has been removed or replaced by ‘protein complexes’. 
Janardhan HP, Milstone ZJ, Shin M, Lawson ND, Keaney JF Jr, Trivedi CM. 
Hdac3 regulates lymphovenous and lymphatic valve formation. 
J Clin Invest. 2017 Nov 1;127(11):4193-4206 
This work is licensed under the Creative Commons Attribution 4.0 
International License. http://creativecommons.org/licenses/by/4.0/. 
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Abstract  
Lymphedema, the most common lymphatic anomaly, involves defective 
lymphatic valve development; yet the epigenetic modifiers underlying 
lymphatic valve morphogenesis remain elusive. Here, we showed that during 
mouse development, the histone-modifying enzyme histone deacetylase 3 
(Hdac3) regulates the formation of both lymphovenous valves, which maintain 
the separation of the blood and lymphatic vascular systems, and the 
lymphatic valves. Endothelium-specific ablation of Hdac3 in mice led to blood-
filled lymphatic vessels, edema, defective lymphovenous valve 
morphogenesis, improper lymphatic drainage, defective lymphatic valve 
maturation, and complete lethality. Hdac3-deficient lymphovenous valves and 
lymphatic vessels exhibited reduced expression of the transcription factor 
Gata2 and its target genes. In response to oscillatory shear stress, the 
transcription factors Tal1, Gata2, and Ets1/2 physically interacted with and 
recruited Hdac3 to the evolutionarily conserved E-box–GATA–ETS composite 
element of a Gata2 intragenic enhancer. In turn, Hdac3 recruited histone 
acetyltransferase Ep300 to form a complex that promoted Gata2 expression. 
Together, these results identify Hdac3 as a key epigenetic modifier that 
maintains blood-lymph separation and integrates both extrinsic forces and 
intrinsic cues to regulate lymphatic valve development. 
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Introduction 
Thin-walled lymphatic capillaries collect interstitial fluid (lymph) and transport 
it via collecting lymphatic vessels to the thoracic duct, which in turn drains into 
the subclavian vein (Yang and Oliver, 2014). Improper drainage of this 
extravasated protein-rich fluid from the tissues causes it to accumulate, 
resulting in lymphedema (Alitalo, 2011). Intraluminal lymphatic valves within 
the collecting lymphatic vessels and bicuspid lymphovenous valves ensure 
anterograde lymph drainage into the venous circulation (El Zawahry, 1983). 
Additionally, these valves prevent backflow of venous blood into the thoracic 
and right lymphatic ducts, effectively separating the blood and lymphatic 
systems (Hess et al., 2013; Srinivasan et al., 2011). Platelet-mediated 
intervascular hemostasis also functions with lymphovenous valves to maintain 
this separation throughout life (Hess et al., 2013). Developmental or functional 
defects in these valves can cause both primary and secondary lymphedema 
(Jurisic and Detmar, 2009; Petrova et al., 2004). 
Lymphatic endothelial cells (LECs), the building blocks of the mammalian 
lymphatic vasculature, experience shear stress generated by the cephalad 
movement of lymphatic fluid (Sabine et al., 2012). Recent evidence 
demonstrates that this oscillatory lymph flow–mediated shear stress initiates 
stepwise morphological and molecular changes within LECs that lead to the 
formation of lymphatic valves (Kazenwadel et al., 2015; Sabine et al., 2012; 
Sweet et al., 2015; Tatin et al., 2013). Specifically, oscillatory shear stress 
(OSS) induces the expression of genes, including GATA2, FOXC2, GJA4, 
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and ITGA9, in LECs that are important for lymphatic valve development 
(Kazenwadel et al., 2015; Sabine et al., 2015; Sweet et al., 2015). GATA2, an 
upstream transcriptional regulator of FOXC2, PROX1, GJA4, and ITGA9, is 
important for blood-lymph separation and the development of lymphovenous 
and lymphatic valves (Brouillard et al., 2014; Kazenwadel et al., 2015; Lim et 
al., 2012; Sweet et al., 2015). Despite this evidence, the mechanisms driving 
OSS-mediated GATA2 expression during lymphatic valve development 
remain elusive. 
GATA2 belongs to an evolutionarily conserved family of zinc finger 
transcription factors that play important roles in diverse developmental 
programs (Bresnick et al., 2010; Tsai et al., 1994). Monoallelic missense 
mutations and intragenic microdeletions in human GATA2 cause Emberger 
syndrome, characterized by primary lymphedema with a predisposition to 
myelodysplastic syndrome or acute myeloid leukemia (Mansour et al., 2010; 
Ostergaard et al., 2011). Moreover, 2 recurrent mutations that cause reduced 
GATA2 expression (c.1017+512del28 and c.1017+572C>T) within a highly 
conserved 167-bp intragenic enhancer of intron 5 of GATA2 have been found 
in patients with primary lymphedema (Ganapathi et al., 2015; Hsu et al., 2013; 
Spinner et al., 2014). Recent studies in transgenic mice demonstrate that this 
intragenic enhancer confers GATA2 expression specifically within endothelial 
cells of the lymphatic, cardiac, and vascular systems (Khandekar et al., 2007; 
Lim et al., 2012). Indeed, murine embryos lacking this Gata2 intragenic 
enhancer have reduced Gata2 expression and phenocopy the endothelial 
knockout of Gata2 (Johnson et al., 2012). Thus, there is strong evidence that 
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reduced GATA2 expression leads to lymphedema (Kazenwadel et al., 2012; 
2015; Spinner et al., 2014). 
Broadly, enhancers function as cis-regulatory elements controlling gene 
expression in a spatiotemporal and cell type–specific manner (Ong and 
Corces, 2011). Enhancer element activation is dependent on recruitment of 
specific transcription factors, coactivators, chromatin remodelers, and histone-
modifying enzymes (Long et al., 2016). The latter establish histone marks that 
often serve to recruit a multitude of transcription factors and cofactors to gene 
regulatory elements (Calo and Wysocka, 2013; Ong and Corces, 2011). In 
addition, active enhancers show enrichment of Lys-27 acetylation on histone 
H3 (H3K27ac) and occupancy of the histone acetyltransferase EP300 
(Creyghton et al., 2010; Rada-Iglesias et al., 2010; Zhang et al., 2013). While 
the complex regulation of enhancer elements is starting to be defined, the role 
of histone-modifying factors in regulating the transcriptional activity of the 
Gata2 intragenic enhancer remains unknown. 
Two opposing classes of histone-modifying enzymes, histone 
acetyltransferases (HATs) and histone deacetylases (HDACs), regulate the 
acetylation state of histones within an enhancer (Yang and Seto, 2008). 
Acetylation by HATs is generally associated with transcriptional activation, 
while HDAC-mediated deacetylation usually results in transcriptional 
repression (Yang and Seto, 2008). On the basis of their catalytic mechanism 
and sequence homology, HDACs are classified into 5 subfamilies: class I 
(Hdac1, 2, 3, and 8), class IIa (Hdac4, 5, 7, and 9), class IIb (Hdac6 and 10), 
class III (Sirt1, 2, 3, 4, 5, 6, and 7), and class IV (Hdac11) (Montgomery et al., 
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2008). Among HDACs, global loss of class I HDACs in mice causes 
embryonic or neonatal lethality, suggesting that these enzymes play pivotal 
roles in development (Bhaskara et al., 2008; Haberland et al., 2009a; Lagger, 
2002; Montgomery et al., 2008; Trivedi et al., 2007). Recent studies from our 
laboratory and others have identified unique and tissue-specific functions of 
ubiquitously expressed class I HDACs during cardiac and craniofacial 
development (Haberland et al., 2009a; Lewandowski et al., 2015; Trivedi et 
al., 2008; 2010). Class I HDACs lack intrinsic DNA-binding domains and are 
instead recruited to the chromatin in a signal-dependent manner via their 
interactions with multiple protein nuclear complexes, transcription factors, and 
cofactors (Yang and Seto, 2008). Contrary to previous assumptions, emerging 
data from genome-wide mapping reveal that the majority of HATs and class I 
HDACs are recruited to promoter and enhancer regions of actively transcribed 
genes with acetylated histones (Wang et al., 2009). Among class I HDACs, 
Hdac3 mainly occupies intragenic and intergenic regions, including enhancers 
marked by H3K27ac and EP300 enrichment (Feng et al., 2011; You et al., 
2013; Zhang et al., 2016; Mullican et al., 2008). Despite advances in 
understanding the developmental roles of class I HDACs, their role in vascular 
and lymphatic development remains undefined. 
Here, we show that endothelial Hdac3, but not Hdac1 or Hdac2, is important 
for blood lymphatic separation. Mice lacking endothelial Hdac3 demonstrate 
congenital lymphedema due to defective lymphovenous and intraluminal 
lymphatic valve development. Our studies reveal that Hdac3-mediated 
epigenetic regulation of an OSS-dependent Gata2 intragenic enhancer 
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orchestrates lymphatic valve development and establishes blood-lymph 
separation. 
 
Results 
Lymphatic endothelial Hdac3 regulates blood-lymph separation 
Hdac3 is ubiquitously expressed, including within LECs of developing 
lymphovenous valves, mesenteric lymphatic vessels and valves, heart, and 
peripheral lymphatic vessels (Figure 2.1, A–G (Emiliani et al., 1998; 
Lewandowski et al., 2014; 2015; Yang et al., 1997). Germline deletion of 
Hdac3 results in embryonic lethality before E9.5 (Bhaskara et al., 2008; 
Montgomery et al., 2008). To determine the function of Hdac3 in the 
developing blood and lymphatic vasculature, we deleted Hdac3 in endothelial 
cells using Hdac3fl/fl mice and 3 Cre lines: Tek-Cre (Hdac3TekKO), Cdh5-Cre 
(Hdac3Cdh5KO), and Lyve1-Cre (Hdac3Lyve1KO) (Figure 2.1, A, D, and G) (Alva 
et al., 2006; Kisanuki et al., 2001; Pham et al., 2010).  
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Figure 2.1 
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Figure 2.1 Hdac3 is ubiquitously expressed in the developing lymphatic 
vasculature - (A) Whole-mount co-immunofluorescent staining of P5 
Hdac3Cdh5KO mesenteric lymphatic vessels reveals loss of Hdac3 expression 
(red) in Vegfr3+ (green) LECs (red arrow) compared to control (white arrow). 
Sub-stack of Z-stack images are presented. (B-C) Whole-mount co-
immunofluorescent staining of E17.5 (B) or P0 (C) murine mesenteric 
lymphatic vessels identifies Hdac3 (red) expression in Pdpn+ lymphatic 
vessels (white arrows). (D) Hdac3 immunostaining of LacZ stained P0 
Hdac3Cdh5KO; R26RLacZ+/- heart section show loss of Hdac3 protein expression 
(red arrows) in LacZ+ cells compared to control (black arrows). (E-G) Co-
immunofluorescent stain for Lyve1 (lymphatic marker – green) and Hdac3 
(red) shows Hdac3 expression (white arrows) in LECs forming lymphovenous 
valves and lymph sac at E13.5 (E), cardiac lymphatic vessel at P8 (K), and 
peripheral embryonic lymphatic vessels at E17.5 (G). E17.5 Hdac3Lyve1KO 
peripheral lymphatic vessel (G) reveals loss of Hdac3 expression in Lyve1+ 
(green) LECs (red arrow) compared to control (white arrow). Green arrows 
(G) show blood-filled peripheral lymphatic vessels. LV, lymphatic valve; SVC, 
superior vena cava; LS, lymph sac; LVV, lymphovenous valve; A, Artery; IJV, 
internal jugular vein; SCV, subclavian vein. Scale bar, 100µm (A-F); Scale 
bar, 50µm (G). 
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Hdac3TekKO mice were identified until E14.5 but not at birth (P0), indicating 
complete embryonic lethality (Tables 2.1 and 2.2). Hdac3TekKO embryos 
showed ectatic superficial vessels, pooling of blood in the jugular region, and 
severe edema at E14.5 compared with that seen in E12.5 embryos (Figure 
2.2A). Hdac3Cdh5KO and Hdac3Lyve1KO neonates revealed similar ectatic dermal 
vessels at P6 and P0 and neonatal lethality at P9 and P0, respectively (Figure 
2.2, B and C, and Tables 2.3 and 2.4). Endothelial cells lining blood-filled 
superficial vessels in Hdac3TekKO embryos and Hdac3Cdh5KO neonates were 
positive for the lymphatic marker Lyve1, but negative for the venous marker 
Emcn, suggesting lymphatic identity (Figure 2.2, D and E).  
Additionally, Hdac3Cdh5KO neonates exhibited blood-filled lymphatic vessels in 
intestine and mesentery between P5 and P6 and in heart at P0 (Figure 2.2, 
F–H). Similarly, Hdac3Lyve1KO neonates had blood-filled cardiac lymphatic 
vessels at P0 (Figure 2.2I). We observed no apparent structural defects in 
Hdac3Cdh5KO or Hdac3Lyve1KO hearts (Figure 2.3, A and B).  
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Table 2.1 
 
 
 
 
Table 2.2 
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Figure 2.2 
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Figure 2.2 Lymphatic endothelial Hdac3 regulates blood-lymphatic 
separation. (A) Dissected E12.5 and E14.5 Hdac3TekKO embryos. Green arrow 
shows ectatic superficial vessels; black arrow shows pooling of blood in the 
jugular region; red arrow shows swelling. (B and C) Neonatal (P6) 
Hdac3Cdh5KO mice (B) and P0 Hdac3Lyve1KO mice (C) had abnormal blood-filled 
dermal vessels (green arrows) compared with controls. (D–F) H&E and 
coimmunofluorescence staining for Lyve1 (lymphatic marker, red) and Emcn 
(venous marker, green) shows blood-filled (green arrows) dermal lymphatic 
vessels in E14.5 Hdac3TekKO murine embryos (D) and blood-filled dermal (E) 
and intestinal lymphatic vessels (F) in P6 Hdac3Cdh5KO neonates (E and F). 
White arrows show lymphatic vessels. (G) Dissected intestine of control and 
Hdac3Cdh5KO P6 neonates. White, red, and blue arrows indicate lymphatic, 
arterial, and venous vessels, respectively; black arrow shows a mesenteric 
lymph node; green arrows show blood-filled lymphatic vessels and a 
mesenteric lymph node in Hdac3Cdh5KO P6 neonates. (H and I) P8 
Hdac3Cdh5KO (H) and P0 Hdac3Lyve1KO (I) hearts show ectatic and hemorrhagic 
superficial vessels (green arrows). H&E and coimmunofluorescence staining 
for Lyve1 (lymphatic marker, red) and Emcn (venous marker, green) shows 
blood-filled (green arrows) cardiac lymphatic vessels in P8 Hdac3Cdh5KO (H) 
and P0 Hdac3Lyve1KO (I) murine hearts. White arrows show lymphatic vessels. 
Scale bars: 100 µm. A, artery; LV, lymphatic vessel; MLN, mesenteric lymph 
node; V, vein. See also Figures 2.1, 2.3–5 and Tables 2.1–2.5. 
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Table 2.3 
                
 
Table 2.4 
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Figure 2.3 
 
 
 
       
 
 
 
 
 
Figure 2.3 Endothelial Hdac3 is dispensible for myocardial development. (A-
B) H&E-stained sections show normal myocardial development in 
Hdac3Cdh5KO P8 (A) or Hdac3Lyve1KO P0 (B) hearts. Scale bar, 1000µm. 
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Table 2.5 
  
   Phenotypes of mice lacking endothelial Hdac3 
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Among class I HDACs, murine embryos lacking Hdac1 or Hdac2 in the 
endothelial cells (Hdac1TekKO or Hdac2TekKO) appeared normal, with complete 
segregation of blood and lymphatic vasculature (Figure 2.4, A and B).   
           To determine whether ubiquitously expressed Hdac3 functions within 
platelets to maintain separation of the venous and lymphatic vasculature 
during development, we deleted Hdac3 in the platelets using PF4-iCre 
(Hdac3PF4KO) (Tiedt et al., 2007). Hdac3PF4KO neonatal mice were viable, 
appeared normal, and displayed complete blood-lymph separation (Figure 
2.5, A–S). Together, these results suggest that Hdac3 functions in LECs to 
regulate separation of the blood and lymphatic systems during development. 
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Figure 2.4 
                      
                     
    
 
Figure 2.4 Dissected E14.5 Hdac1TekKO (A) and Hdac2TekKO (B) embryos 
appear normal. Lymphatic vessels in E14.5 Hdac1TekKO and Hdac2TekKO 
embryos do not show blood cells (black arrows). Scale bar, 100µm. 
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Figure 2.5 
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Figure 2.5 Platelet Hdac3 is dispensable for blood-lymphatic separation. (A-
B) Hdac3PF4KO mice do not show hindlimb edema (B) compared to control (A). 
(C-F) Perinatal (P6) Hdac3PF4KO mice do not display abnormal blood-filled 
dermal vessels (D, F) compared to control (C, E). (G-J) Hdac3PF4KO heart 
does not show ectatic and hemorrhagic superficial vessels at P6 (H, J) 
compared to control (G, I). (K-L) Dissected P6 Hdac3PF4KO mice do not show 
blood-filled thoracic duct (L, arrow) compared to chyle-filled thoracic duct (K, 
black arrow) in control.  (M-R) Hdac3PF4KO P6 mice show normal chyle-filled 
white mesentery lymph node (N), intestinal lymphatic vessels (Q), and 
mesenteric lymphatic vessels (R) compared to control (M, O, P). (S) 
Hdac3Cdh5KO P6 mice show normal platelet counts compared to control. Data 
represent the mean ± SEM and are representative of three independent 
experiments. P values are determined by Student’s t test. N.S., not significant.  
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Hdac3 regulates lymphovenous valve development. Bicuspid lymphovenous 
valves, located at the thoracic duct–subclavian vein junction and right 
lymphatic duct–subclavian vein junction, maintain the separation between the 
high-pressure vascular system and the low-pressure lymphatic system (Hess 
et al., 2013; Srinivasan et al., 2011). To investigate blood pooling in the 
jugular region of the embryos lacking endothelial Hdac3 (Figure 2.2B), we 
examined the morphology of developing lymphovenous valves and lymph sac 
in transverse and coronal sections (Figure 2.6, A–C). Embryos lacking 
endothelial Hdac3 displayed abnormal blood-filled lymph sacs at various 
developmental stages (Figure 2.6, D, F, and G, and Figure 2.7). Endothelial 
cells lining blood-filled lymph sacs in Hdac3-null embryos revealed similar 
expression levels of Lyve1 or Vegfr3 (Figure 2D and Figure 2.7). Consistent 
with this observation, the thoracic duct in Hdac3Cdh5KO neonates showed 
infiltration of blood into the normally lymph-filled duct, suggesting a functional 
lymphovenous valve defect (Figure 2.6, E). Indeed, Hdac3TekKO, Hdac3Cdh5KO, 
and Hdac3Lyve1KO embryos displayed shortened lymphovenous valve leaflets 
with defective perpendicular alignment to the flow direction (Figure 2.6, F–H). 
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Figure 2.6 
                  
 
                
	 59	
                                 
 
                         
 
	 60	
                         
 
                         
 
	 61	
Figure 2.6 Hdac3 is an important regulator of lymphovenous valve 
development. (A–C) Schematic model depicting normal anatomy of a 
developing murine lymphovenous valve (A, black arrow) in transverse (B) and 
coronal (C) planes. (D) Transverse sections of E14.5 Hdac3TekKO embryos 
revealed bloodfilled lymph sacs (orange arrows) lined by lymphatic (Lyve1 
immunostaining [red], white arrows), but not venous (Emcn immunostaining, 
green), endothelial cells compared with that seen in controls. (E) Dissected 
P5 Hdac3Cdh5KO mice had a blood-filled thoracic duct (green arrow) compared 
with a chyle-filled thoracic duct in control mice (black arrow). (F) H&E-stained 
coronal sections of an E13.5 Hdac3TekKO embryo revealed a blood-filled lymph 
sac (orange arrow) and disrupted morphology of the lymphovenous valves 
(green arrows) compared with controls (yellow arrows). Immunofluorescence 
staining for podoplanin (Pdpn) (green) and Lyve1 (red) showed overlapping 
expression (yellow) in E13.5 LVVs. Orange arrow indicates a blood-filled 
lymph sac. (G and H) H&E-stained coronal sections of E17.5 Hdac3Cdh5KO (G) 
and Hdac3Lyve1KO (H) embryos revealed disrupted morphology of the 
lymphovenous valves (blue arrows) compared 
with controls (green arrows). Orange arrow shows a blood-filled lymph sac. 
Lyve1 (red) was expressed in E17.5 murine lymphovenous valves (G and H). 
Emcn (green, venous marker) was used as a negative control for 
lymphovenous valves (H). IJV, internal jugular vein; LS, lymph sac; LVV, 
lymphovenous valve; SVC, superior vena cava; TD, thoracic duct. Scale bars: 
100 µm and 50 µm (F, bottom panels, G, and H). See also Figure 2.7 and 
Table 2.5. 
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Figure 2.7 
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Figure 2.7	Endothelial Hdac3 is a critical regulator of blood-lymphatic 
seperation at a early stage of development. (A-D) Whole-mount LacZ staining 
of control (A, C, C’) and Hdac3Cdh5KO; R26RLacZ/+ (B) or Hdac3TekKO; R26RLacZ/+  
(D, D’) at E11.5 and E12.5, respectively, show similar level and pattern of 
LacZ expression. (E-H) H&E-stained transverse sections of LacZ-stained 
E12.5 Hdac3TekKO (E, F) embryos reveal blood-filled lymph sacs (F’, H’ red 
arrows) compared to control (E’, G’). Vegfr3 immunostaining (G-H) shows 
LECs-specific expression (G’, H’, black arrows) in LacZ+ (G’, H’, green 
arrows) E12.5 murine lymph sac. (I-J) Schematic model depicting loss of 
blood-lymphatic separation between SVC and TD due to defective 
lymphovenous valve development in Hdac3-null mice. H&E, Hematoxylin and 
Eosin; CV, cardinal vein; LS, lymph sac. Scale bar, 100mm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 65	
Hdac3 regulates proper lymphatic transport and mesenteric lymphatic valve 
maturation. Dysfunctional intraluminal lymphatic valves in collecting lymphatic 
vessels impede the ability of the lymphatic system to effectively transport 
lymph, leading to lymphedema (Jurisic and Detmar, 2009; Petrova et al., 
2004). To study the lymph transport in Hdac3Cdh5KO neonates, we determined 
retrograde lymphatic flow reflux using Evans blue dye (Figure 2.8, A–E). 
Hdac3Cdh5KO neonates had abnormal retrograde flow of Evans blue dye into 
the tail, right hind limb, abdomen, dermal lymphatic vessels, mesenteric 
lymphatic vessels, and mesenteric lymph nodes (Figure 2.8, A–D). We also 
observed Evans blue dye in intercostal lymphatics lateral to the thoracic duct 
in the thoracoepigastric region, coupled with reduced contrast drainage into 
the thoracic duct in Hdac3Cdh5KO neonates compared with the control (Figure 
2.8E), suggesting a severe impairment of lymph transport. Consistent with this 
observation, Lyve1+ dermal lymphatic capillaries revealed anomalous 
recruitment of smooth muscle cells in P6 Hdac3Cdh5KO neonates (Figure 2.8F). 
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Figure 2.8 
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Figure 2.8	 Hdac3 deficiency causes impaired lymphatic drainage and 
anomalous lymphatic valve development in mesenteric lymphatic vessels. (A 
and B) Evans blue dye injection into the left hind paw (A and B, white arrows) 
of P5 Hdac3Cdh5KO mice showed reflux (retrograde flow) into the tail, right hind 
limb, and abdomen (A and B, red arrows) compared with an absence of reflux 
in the control mice (black arrows). Original magnification ×2.5. (C and D) P5 
Hdac3Cdh5KO mice showed Evans blue dye reflux (red arrows) into dermal 
lymph vessels and mesenteric lymph nodes compared with control mice 
(dotted line, black arrows). Original magnification ×3. (E) Control P5 mice 
showed normal unidirectional cephalad drainage restricted to the thoracic duct 
(black arrow). Hdac3Cdh5KO mice exhibited reflux into the intercostal lymphatics 
lateral to the thoracic duct in the thoracoepigastric region (red arrows) and 
reduced drainage into the thoracic duct (green arrow). (F) 
Coimmunofluorescence staining for Lyve1 (green) and smooth muscle actin 
(SMA) (red) showed abnormal smooth muscle recruitment (white arrows) to 
blood-filled dermal lymphatic capillaries in P6 Hdac3Cdh5KO mice compared 
with controls. (G) Quantitation of lymphatic valve territories in E17.5 
Hdac3Lyve1KO mesenteric lymphatic vessels. The P value was determined by 
unpaired Student’s t test. (H–J) Whole-mount coimmunofluorescence staining 
of Hdac3Lyve1KO (H and I) and Hdac3Cdh5KO (J) mesenteric lymphatic vessels 
showed a lack of Prox1-expressing (red) lymphatic valves in Pecam1+ 
(green) lymphatic vessels (yellow arrows) compared with controls (white 
arrows). (K and L) Whole-mount coimmunofluorescence staining of 
Hdac3Lyve1KO (K) and Hdac3Cdh5KO (L) mesenteric lymphatic vessels 
showed a lack of Itga9-expressing (green) lymphatic valves in Prox1+ (red) 
lymphatic vessels (yellow arrows) compared with controls (white arrows). (M 
and N) Whole-mount coimmunofluorescence staining of Hdac3Lyve1KO (M) and 
Hdac3Cdh5KO (N) mesenteric lymphatic vessels showed excessive SMA (red) 
coverage (yellow arrows) compared with controls (white arrows). Vegfr3 
(green) was used as a lymphatic vessel marker. Data represent the mean ± 
SEM and are representative of 3 independent experiments. Sub-stacks of Z-
stack images are presented in H–N. Scale bars: 100 µm (F) and 1 µm (H–N). 
See also Figure 2.9. 
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Additionally, Hdac3-deficient mesenteric lymphatic vessels showed immature 
and reduced numbers of lymphatic valves at various stages of development 
(Figure 2.8, G–N, and Figure 2.9, A–D). Prox1 and Pecam1 whole-mount 
immunofluorescence costaining analyses revealed fewer and disorganized 
Prox1Hi LEC clusters in Hdac3Cdh5KO and Hdac3Lyve1KO lymphatic vessels 
(Figure 2.8, H–J, and Figure 2.9, A–D). Hdac3Cdh5KO and Hdac3Lyve1KO 
lymphatic vessels showed reduced integrin-α9 expression within lymphatic 
valve sites (Figure 2.8, K and L). In addition, Hdac3-deficient lymphatic 
collecting vessels exhibited excessive smooth muscle cell coverage 
compared with controls (Figure 2.8, M and N). 
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Figure 2.9 
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Figure 2.9 Whole-mount co-immunofluorescent staining of E17.5 
Hdac3Lyve1KO mesenteric lymphatic vessels show reduced number of Prox1 
(red) expressing valve forming territories in Pecam1+ (green) lymphatic 
vessels (red arrows) compared to control (white arrows). (B) Quantitation of 
lymphatic valves in P0 Hdac3Lyve1KO mesenteric lymphatic vessels. (C) Whole-
mount co-immunofluorescent staining of P5 Hdac3Cdh5KO mesenteric 
lymphatic vessels lake mature Prox1 (red) expressing valves in Pecam1+ 
(green) lymphatic vessels (red arrows) compared to control (white arrows). 
(D) Quantitation of lymphatic valves in P5 Hdac3Cdh5KO mesenteric lymphatic 
vessels. Data represent the mean ± SEM and are representative of three 
independent experiments. P values are determined by Student’s t test. Scale 
bar, 100µm. 
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Hdac3 regulates Gata2 expression in developing lymphovenous and 
lymphatic valves. Transcriptional analysis of mesenteric lymphatic vessels 
dissected from Hdac3Cdh5KO neonates revealed downregulation of genes 
required for lymphatic valve development (Kazenwadel et al., 2015; Sabine et 
al., 2015; Sweet et al., 2015), such as Gata2, Foxc2, Gja4, and Itga9 (Figure 
2.10A). Hdac3Cdh5KO lymphatic vessels had endothelial marker gene transcript 
expression levels similar to those observed in controls (Figure 2.11A). Loss of 
Hdac3 in mesenteric lymphatic endothelium also resulted in reduced Prox1 
expression (Figure 2.10B).  
Consistent with this observation, we found that Hdac3Lyve1KO lymphatic 
vessels had downregulated expression of Gata2 and Foxc2 (Figure 2.10C). 
Using laser-capture microdissection (LCMD), we collected lymphovenous 
valves from serial coronal sections of E13.5 murine embryos (Figure 2.11, B–
D). Hdac3TekKO lymphovenous valves revealed similar expression levels of 
endothelial marker gene transcripts (Figure 2.11D), but downregulation of 
Gata2, Foxc2, Gja4, and Itga9 transcripts, compared with expression levels in 
controls (Figure 2.10D). Consistent with this observation, IHC revealed 
reduced expression of Gata2, Foxc2, and Prox1 in the developing Hdac3TekKO 
lymphovenous valves (Figure 2.10, E–G). 
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Figure 2.10 
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Figure 2.10	Hdac3 regulates Gata2 and its target gene expression in 
developing lymphatic valves and lymphovenous valves. (A) Transcripts 
for Gata2, Foxc2, Gja4, and Itga9 were detected by ChIP-qPCR in control and 
Hdac3Cdh5KO mesenteric lymphatic vessels dissected from P5 
mice. (B) Whole-mount immunofluorescence staining of Hdac3Cdh5KO 
mesenteric lymphatic vessels identified reduced Prox1 (red) expression 
in Vegfr3+ (red) LECs (red arrows) compared with controls (white arrows). (C) 
Transcripts for Gata2 and Foxc2 were detected by ChIP-qPCR 
in control and Hdac3Lyve1KO mesenteric lymphatic vessels dissected from P0 
mice. (D) Transcripts for Gata2, Foxc2, Gja4, and Itga9 were detected by 
ChIP-qPCR in laser-captured control and Hdac3TekKO lymphovenous valves 
from E13.5 embryos. (E–G) Immunostaining of E13.5 Hdac3TekKO 
lymphovenous valves revealed reduced Gata2 (E, red arrows), Foxc2 (F, red 
arrows), and Prox1 (G, red arrows) expression compared with controls 
(black arrows). LV, lymphatic valve; R, rib. Data represent the mean ± SEM 
and are representative of 3 independent experiments. P values were 
determined by Student’s t test. Scale bars: 500 µm. See also Figure 2.11. 
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Figure 2.11 
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Figure 2.11 (A) Transcripts for Pecam1, Pdpn, and Flt1 were detected by 
real-time qPCR in control and Hdac3Cdh5KO mesenteric lymphatic vessels 
dissected from P5 mice. (B-C) Lymphovenous valves (B, B’, black arrows) 
were microdissected (C, C’, red arrows) from coronal sections of E13.5 
murine embryos using laser capture. (D) Transcripts for Pecam1 and Pdpn 
were detected by real-time qPCR in control and Hdac3TekKO lymphovenous 
valves laser captured from E13.5 embryos. Data represent the mean ± SEM 
and are representative of three independent experiments. P values are 
determined by Student’s t test. SVC, superior vena cava; LS, lymph sac; 
LCM, laser capture microdissection. Scale bar, 100µm. 
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Hdac3 regulates OSS-mediated activation of the Gata2 intragenic enhancer. 
Lymph flow and OSS upregulate genes required for lymphatic valve 
development including Gata2 (Sabine et al., 2012; Sweet et al., 2015). Gata2, 
an important transcription factor for blood-lymph separation and development 
of lymphovenous and lymphatic valves, is an upstream transcriptional 
regulator of Foxc2, Prox1, Gja4, and Itga9 (Brouillard et al., 2014; 
Kazenwadel et al., 2015; Lim et al., 2012; Sweet et al., 2015). In addition, the 
Gata2 intragenic enhancer is both sufficient and necessary to drive Gata2 
expression within LECs (Khandekar et al., 2007; Lim et al., 2012). Ablation of 
this Gata2 intragenic enhancer in mice is sufficient to reduce Gata2 
expression and phenocopy the endothelial knockout of Gata2 (Johnson et al., 
2012). Hence, we examined the mechanism by which Hdac3 regulates Gata2 
expression. To investigate whether Hdac3 regulates Gata2 expression in 
response to shear stress, we analyzed LECs cultured under static or OSS 
conditions (Figure 2.12A). LECs showed upregulation of Gata2, Foxc2, and 
Gja4 in response to OSS, and Hdac3 knockdown abolished this effect (Figure 
2.12B and Figure 2.13A). Catalytically inactive enzymes are frequently 
present in most enzyme families including HDACs (Adrain and Freeman, 
2012). The biological functions of these pseudoenzymes remain largely 
unknown. To determine whether deacetylase activity or chromatin recruitment 
of Hdac3 is required to regulate Gata2 expression in response to OSS, we 
overexpressed 2 different mutant forms of human HDAC3 in Hdac3-deficient 
LECs. The first mutant, HDAC3HEBI, exhibits no enzymatic activity or 
chromatin recruitment, while  
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Figure 2.12 
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Figure 2.12	Hdac3 regulates oscillatory shear stress–mediated activation of 
the Gata2 intragenic enhancer. (A) Schematic of in vitro OSS assay. (B) 
Transcripts for Gata2 were detected by ChIP-qPCR in scrambled shRNA– 
(Sc-shRNA) or Hdac3 shRNA–infected LECs subjected to static or OSS 
conditions and coinfected with GFP, HDAC3, HDAC3H134A,H135A, or HDAC3HEBI 
lentiviruses. (C) Schematics of luciferase reporter vectors composed of WT 
(168 bp), c.1017+512del28 (28-bp deletion, green box, 140 bp), and the 
c.1017+572C>T point mutation (blue box) GATA2 intragenic enhancer. (D) A 
dual luciferase assay was performed in LECs transfected with WT, 
c.1017+512del28, or the c.1017+572C>T point mutation GATA2 intragenic 
enhancer luciferase reporter and subjected to static or OSS conditions. 
Induction is represented as a ratio of firefly to Renilla luciferase activity. (E) 
Scramble shRNA– or Hdac3 shRNA–infected LECs, cotransfected with the 
WT GATA2 intragenic enhancer luciferase reporter, were subjected to static 
or OSS conditions. Induction is represented as a ratio of firefly to Renilla 
luciferase activity. Data represent the mean ± SEM and are representative of 
3 independent experiments. P values were determined by Student’s t test (B 
and D) or by 1-way ANOVA with Sidak’s multiple comparisons test (E). See 
also Figures 2.13 and 2.14 
 
	 85	
Figure 2.13 
 
 
 
 
Figure 2.13 (A) Transcripts for Foxc2 and Gja4 were detected by real-time 
qPCR in Sc- or Hdac3-shRNA-infected LECs subjected to static or OSS and 
co-infected with GFP lentiviruses. (B) Total lysates from LECs expressing 
flag-tagged HDAC3, HDAC3HEBI, or HDAC3H134A, H135A plasmids were 
analyzed by Western blot using anti-Flag antibody. a-Tubulin is shown as a 
loading control. Data represent the mean ± SEM and are representative of 
three independent experiments. P values are determined by one-way ANOVA 
using Sidak’s multiple comparisons test. OSS, oscillatory shear stress; Sc, 
scramble.   
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the second mutant, HDAC3H134A, H135A, lacks enzymatic activity but has 
preserved chromatin recruitment (Lewandowski et al., 2015; Sun et al., 2013).  
Flag-tagged WT and mutant HDAC3 plasmids showed similar levels of 
expression within LECs (Figure 2.13B). Expression of either WT Hdac3 or 
HDAC3H134A, H135A rescued Gata2 expression, whereas HDAC3HEBI expression 
failed to do so (Figure 2.12B). These data indicate that Hdac3 functions in a 
chromatin-dependent, but deacetylase-independent, manner to regulate 
Gata2 expression within LECs in response to OSS. The intron 5 168-bp 
GATA2 intragenic enhancer region is highly conserved (Figure 2.14).  
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Figure 2.14 
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Figure 2.14 UCSC genome browser view of human GATA2 locus. Based on 
ChIP-seq data curated by the ENCODE project consortium, GATA2 intragenic 
enhancer region (orange highlight) is enriched for H3K27ac and EP300. 168 
bp GATA2 intragenic enhancer region shows high degree of evolutionary 
conservation in multiple alignments of 100 vertebrate species (red arrow). 
Specifically, the sequence encompassing c.1017+512del28 mutation region 
(green box) and c.1017+572C>T point mutation (blue box), observed in 
patients with lymphedema, is highly conserved among mammals. The E-box 
sequence (red box) is located within the c.1017+512del28 deletion region 
(green box) while the c.1017+572C>T point mutation is within the ETS binding 
site (orange box). Consensus GATA binding site (purple box) is located 
between E-box and ETS binding sites.  
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Tal1, Gata2, and Ets1/2 recruit Hdac3 to the Gata2 intragenic enhancer in a 
shear stress–dependent manner. To investigate the mechanisms by which 
Hdac3 regulates the Gata2 intragenic enhancer, we determined enrichment of 
Hdac3 at the Gata2 intragenic enhancer region in LECs cultured under static 
or OSS conditions. Hdac3 occupancy at the Gata2 intragenic enhancer was 
increased under OSS compared with that observed under static conditions, 
suggesting that lymphatic flow regulates the recruitment of Hdac3 to 
chromatin (Figure 2.15A). TRANSFAC (TRANScription FACtor database; 
http://genexplain.com/transfac/) analysis of ENCODE (Encyclopedia of DNA 
Elements; https://www.encodeproject.org/) ChIP-sequencing (ChIP-seq) data 
sets suggested a composite occupancy of the transcription factors Tal1, 
Gata2, and Ets1/2 at the E-box–GATA–ETS element of the Gata2 intragenic 
enhancer (Figure 2.15B). ChIP–quantitative PCR (ChIP-qPCR) analysis 
confirmed enrichment of Tal1, Gata2, and Ets1/2 at the Gata2 intragenic 
enhancer region in LECs under static conditions (Figure 2.15C). To test the 
physical interaction of Hdac3 with Tal1, Gata2, or Ets1/2, we performed 
immunoprecipitation of endogenous Hdac3 protein from LECs cultured under 
static or OSS conditions, followed by immunoblotting for Tal1, Gata2, or  
Ets1/2. We found that OSS induced a physical interaction between Hdac3 and 
Tal1, Gata2, or Ets1/2 in LECs (Figure 2.15, D and E). Notably, total 
expression of Hdac3 protein and Tal1 and Ets1 transcripts remained 
unchanged in LECs in response to OSS (Figure 2.15D and Figure 2.16A).  
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Figure 2.15 
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Figure 2.15 Tal1, Gata2, and Ets1/2 recruit Hdac3 to the Gata2 intragenic 
enhancer in response to lymphatic shear stress. (A) ChIP-qPCR analysis of 
Hdac3 recruitment to the Gata2 intragenic enhancer was performed in LECs 
subjected to static conditions or OSS. (B) Schematic model depicting 
TRANSFAC analysis of ENCODE ChIP-seq data sets at the E-box–GATA–
ETS element of the Gata2 intragenic enhancer. (C) ChIP–qPCR analysis of 
Tal1, Gata2, and Ets1/2 recruitment to the Gata2 intragenic enhancer was 
performed in LECs. (D and E) Total lysates from pooled LECs subjected to 
static or OSS conditions were immunoprecipitated by IgG or Hdac3 antibody, 
and Western blot analysis was performed using Tal1, Gata2, or Ets1/2 
antibody (D). Total Hdac3 and α-tubulin levels are shown as an input control 
(D). Tal1, Gata2, and Ets1/2 expression was quantified and normalized to 
total input using ImageJ software (E). (F) ChIP–qPCR analysis of Hdac3 
recruitment to the Gata2 intragenic enhancer in scrambled shRNA–, Tal1 
shRNA–, Gata2 shRNA–, or Ets1/2 shRNA–infected LECs subjected to OSS 
(n = 3). Data represent the mean ± SEM and are representative of 3 
independent experiments. P values were determined by Student’s t test (C 
and F) or by 1-way ANOVA using Sidak’s multiple comparisons test (A and 
E). WB, Western blotting. See also Figure 2.16. 
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Figure 2.16 
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Figure 2.16 Transcripts for Tal1, Ets1, and Ep300 were detected by real-time 
qPCR in LECs subjected to static or OSS. (B) Transcripts for Hdac3, Ep300, 
Tal1, Ets1, Ets2, and Gata2 were detected by real-time qPCR in Sc- or 
Hdac3/Ep300/Tal1/Ets1/Ets2/Gata2-shRNA-infected LECs respectively. (C) 
Transcripts for Hdac3 and Ep300 were detected by real-time qPCR in Sc-, 
Gata2-, Tal1-, or Ets1/2-shRNA-infected LECs. Data represent the mean ± 
SEM and are representative of three independent experiments. P values are 
determined by Student’s t test (A, B) or by one-way ANOVA using Sidak’s 
multiple comparisons test (C). OSS, oscillatory shear stress; Sc, scramble; 
N.S., not significant. 
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Loss of Tal1, Gata2, or Ets1/2 abolished OSS-dependent recruitment of 
Hdac3 to the Gata2 intragenic enhancer in LECs (Figure 6F and Figure 
2.16B). LECs expressing Tal1, Gata2, or Ets1/2 shRNAs showed similar 
expression levels of Hdac3 transcripts (Figure 2.16C). 
Hdac3 recruits EP300 to the Gata2 intragenic enhancer to promote Gata2 
transcription in response to OSS. To investigate how Hdac3 regulates the 
activation of the Gata2 intragenic enhancer in response to shear stress, we 
determined the enrichment of H3K27ac and EP300 at the Gata2 intragenic 
enhancer in WT and Hdac3-deficient LECs cultured under static or OSS 
conditions. LECs showed enrichment of H3K27ac and EP300 in response to 
OSS, and this enrichment was abolished by Hdac3 knockdown (Figure 2.17, 
A and B, and Figure 2.16B).  
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Figure 2.17 
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Figure 2.17 Hdac3 recruits EP300 to the Gata2 intragenic enhancer in 
response to lymphatic shear stress. (A and B) ChIP–qPCR analysis of H3K27 
acetylation (A) and EP300 recruitment (B) to the Gata2 intragenic enhancer in 
scrambled shRNA– or Hdac3 shRNA–infected LECs subjected to static or 
OSS conditions. (C and D) Total lysates from pooled LECs subjected to static 
or OSS conditions were immunoprecipitated by IgG or EP300 antibody, and 
Western blot analysis was performed using Hdac3 antibody (C). Total Hdac3 
and α-tubulin levels are shown as input controls. Hdac3 expression was 
quantified and normalized to total input using ImageJ software (n = 3) (D). (E) 
Transcripts for Gata2 were detected by ChIP-qPCR in scrambled shRNA– or 
EP300-shRNA–infected LECs subjected to static or OSS conditions. (F) In 
response to OSS, the transcription factors Tal1, Gata2, and Ets1/2 recruit 
Hdac3 to the Gata2 intragenic enhancer,which in turn recruits EP300 to 
promote Gata2 expression. In LECs lacking Hdac3, OSS failed to promote 
EP300 recruitment to the Gata2 intragenic enhancer, histone H3 Lys-27 
acetylation, and, thereby, Gata2 expression. Data represent the mean ± SEM 
and are representative of 3 independent experiments. P values were 
determined by Student’s t test (E) or by 1-way ANOVA with Sidak’s multiple 
comparisons test (A, B, and D). See also Figure 2.16. 
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We observed that Ep300 transcript expression levels remained unchanged in 
LECs in response to OSS (Figure 2.16A). To test the physical interaction of 
Hdac3 and EP300, we performed immunoprecipitation of endogenous EP300 
protein from LECs cultured under static or OSS conditions, followed by 
immunoblotting for Hdac3. OSS induced physical interaction between Hdac3 
and EP300 in LECs (Figure 2.17, C and D). Taken together, these results 
suggest that Hdac3 recruits EP300 to the Gata2 intragenic enhancer in 
response to OSS. By contrast, EP300-deficient LECs failed to demonstrate 
transcriptional activation of Gata2 in response to OSS (Figure 2.17E and 
Figure 2.16B). LECs expressing Tal1, Gata2, or Ets1/2 shRNAs showed 
similar expression levels of Ep300 transcripts (Figure 2.16C). These data 
suggest that EP300 recruitment to the Gata2 intragenic enhancer is important 
for lymphatic flow–dependent Gata2 expression (Figure 2.17F). 
 
Discussion 
This study reveals a unique, unexpected, and nonredundant role of Hdac3 as 
a key regulator of blood-lymph separation during development. Our results 
demonstrate that endothelial inactivation of ubiquitously expressed Hdac3, but 
not Hdac1 or Hdac2, in mice causes embryonic lethality, failure of blood-
lymph separation, lymphedema, and defects in both lymphatic and 
lymphovenous valves. Despite the sequence homology among class I Hdacs, 
these results suggest a unique function of Hdac3 to mediate blood-lymph 
separation during development. 
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To our knowledge, this is the first report of a histone-modifying enzyme 
regulating separation of the blood and lymphatic vascular systems. Recent 
studies revealed that platelets and podoplanin (an LEC receptor) cooperate to 
prevent blood from entering the lymphatic system at the lymphovenous valve 
(Bianchi et al., 2017; Fu et al., 2008; Geng et al., 2016; Hess et al., 2013; 
Schacht, 2003; Uhrin et al., 2010). However, we found that ablation of Hdac3 
in platelets caused no defects in blood-lymph separation (Figure 2.5, A–S), 
suggesting that Hdac3 functions specifically within LECs. Here, we show that 
Hdac3 ablation in LECs prior to lymphovenous valve formation (Hdac3TekKO) 
resulted in a failure of blood-lymph separation at E12.5 and lethality as early 
as E13.5 (Figure 2.7 and Tables 2.1 and 2.2). Similarly, complete loss of 
Hdac3 in LECs after lymphovenous valve formation (Hdac3Cdh5KO or 
Hdac3Lyve1KO) led to a failure of blood-lymph separation soon after birth 
(Figure 2.2, B, C, and E–I), followed by complete neonatal lethality (Tables 
2.3 and 2.4).  
These alternative genetic approaches reveal that the timing of lethality in mice 
lacking LEC Hdac3 coincides with lymphovenous valve dysfunction and 
failure of blood-lymph separation. However, Hdac3-deficient lymphovenous 
valves and lymphatic vessels showed similar podoplanin expression levels 
compared with levels detected in controls (Figure 2.6F and Figure 2.11, A and 
D). 
These results raise an interesting question: How does ubiquitously expressed 
Hdac3 function in a LEC-specific manner during development? Lacking 
intrinsic DNA-binding capacity, Hdac3 must be recruited to the chromatin via 
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its interaction with multiple protein nuclear complexes, transcription factors, 
and cofactors (Yang and Seto, 2008). Emerging data from genome-wide 
mapping reveal that approximately 60% of Hdac3 occupies intragenic and 
intergenic regions including those marked by H3K27ac (Feng et al., 2011; 
Wang et al., 2009; You et al., 2013; Zhang et al., 2016; Mullican et al., 2008). 
This distribution suggests enhancer-specific functions for Hdac3. Enhancers 
recruit a multitude of protein complexes to orchestrate gene expression in a 
temporal, spatial, or cell type–specific manner (Calo and Wysocka, 2013). 
The GATA2 intragenic enhancer is both sufficient and necessary to drive 
GATA2 expression in LECs (Khandekar et al., 2007; Lim et al., 2012). Our 
findings support a model in which Hdac3 functions in concert with EP300 to 
activate, rather than repress, the Gata2 intragenic enhancer and thereby 
establish a specific transcriptional program for LECs. This model challenges 
long-held assumptions that HDACs replace HATs to promote both histone 
deacetylation and repression of transcription. Taken together, our findings 
warrant further investigation of the extent, if any, to which the intragenic and 
intergenic occupancy of HDACs contributes to the regulation of enhancer 
functions that modulate gene expression. 
Our finding that HDAC3 contributes to the function of the GATA2 intragenic 
enhancer dovetails with recent GWAS revealing that the majority of genetic 
variants or mutations associated with human diseases map to the noncoding 
elements in the genome (Tak and Farnham, 2015). A substantial fraction of 
such mutations are thought to disrupt enhancer elements to alter gene 
expression and cause disease; however, only a few examples have been 
	 101	
identified (Cheryl A Scacheri, 2015). Consistent with this notion, patients with 
c.1017+512del28 deletion or a c.1017+572C>T point mutation within the 
evolutionarily conserved GATA2 intragenic enhancer (divergence ~350 million 
years ago) have lymphedema and significantly reduced GATA2 expression 
(Douzery et al., 2004; Ganapathi et al., 2015; Hsu et al., 2013; Spinner et al., 
2014). The present study takes this scenario one step further by revealing that 
Hdac3 functions as an important epigenetic switch to promote complex 
formation at a deeply conserved Gata2 intragenic enhancer element in 
response to OSS. Disruption of the E-box or ETS motif nullifies Hdac3-
mediated induction of Gata2 expression, suggesting that perturbation of these 
regions disrupts the assembly of the Tal1-Gata2-Ets1/2-Hdac3-Ep300 
complex in developing lymphatic endothelium. These results suggest a 
mechanism by which c.107+512del28 or c.107+572C>T mutations cause 
lymphedema. This model supports the hypothesis that protein complexes at 
enhancers function as a transcription activation switch for developmentally 
important transcription factors in response to intrinsic or extrinsic signaling 
cues (Boffelli et al., 2004; Spitz and Furlong, 2012). While we do not yet fully 
understand the nature of the enhancer elements in the developing lymphatic 
system, these studies broaden the role of protein complexes at deeply 
conserved enhancer elements in lymphatic valve development. 
Here, we highlight the integrated nature of extracellular forces and epigenetic 
signatures at the enhancer elements. Our data show that OSS promotes 
assembly of a protein complex containing the transcription factors Gata2, 
Tal1, Ets1/2 and the histone-modifying enzymes Hdac3 and EP300 at the 
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Gata2 intragenic enhancer–specific E-box–GATA–ETS composite element. 
Concentrated clusters of transcription factor recognition motifs within the 
composite element facilitate direct cooperative binding of multiple transcription 
factors prior to enhancer activation (Spitz and Furlong, 2012). Such “priming” 
of enhancer elements allows additional recruitment of both cofactors and 
effectors of signal transduction pathways to integrate intrinsic and extrinsic 
signaling cues during key stages of development (Long et al., 2016). We 
propose that cooperative interactions among Gata2, Tal1, and Ets1/2 at the 
E-box–GATA–ETS composite element lead to priming of the Gata2 intragenic 
enhancer. OSS-mediated mechanotransduction promotes recruitment of 
Hdac3 and thereby EP300 at the primed Gata2 intragenic enhancer to modify 
the epigenetic signature, which in turn rapidly activates Gata2 transcription 
(Figure 7F). In line with this concept, developing LECs subjected to OSS 
exhibit robust upregulation of Gata2, which is important for lymphatic valve 
development (Kazenwadel et al., 2015; Sweet et al., 2015). In addition, 
murine embryos lacking endothelial Tal1 display edema, blood-filled 
superficial vessels, and complete lethality at E14.5 (Schlaeger, 2005). Global 
loss of both Ets1 and Ets2 in murine embryos also causes edema, blood-filled 
dilated superficial vessels, pooling of blood in the jugular region, and complete 
lethality at E15.5 (Wei et al., 2009). These phenotypes appear very similar to 
those in murine embryos lacking endothelial Hdac3. Hence, our data warrant 
a reexamination of Tal1-knockout and Ets1/2-knockout phenotypes to 
determine whether Tal1 and Ets1/2 regulate blood-lymph separation and 
lymphatic valve development. 
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While the transcriptional regulators of Gata2 are defined, the epigenetic 
modifiers remain unknown. Our data identify Hdac3 as a positive 
transcriptional regulator of Gata2. Consistent with this notion, embryos lacking 
endothelial Hdac3 (our observations) or Gata2 (Geng et al., 2016; 
Kazenwadel et al., 2015) show highly similar phenotypes. For instance, 
endothelial ablation of Hdac3 causes shortened lymphovenous valve leaflets 
with defective perpendicular alignment to the flow direction, similar to those 
seen in murine embryos lacking endothelial Gata2 (Geng et al., 2016). Loss of 
endothelial Hdac3 or Gata2 also causes reduced expression of Foxc2 and 
Prox1 within developing murine lymphovenous valves (Geng et al., 2016; 
Kazenwadel et al., 2015). In addition, embryos lacking lymphatic Hdac3 or 
Gata2 have dysplastic mesenteric lymphatic vessels with fewer and 
disorganized valve-forming territories (Kazenwadel et al., 2015). Furthermore, 
Hdac3 or Gata2 ablation in blood endothelial cells causes failure of blood-
lymph separation in murine embryos between E12.5 and E13.5 (Geng et al., 
2016; Kazenwadel et al., 2015). Interestingly, Prox1-CreERT2–mediated 
inducible Gata2 ablation in lymphatic vasculature at E10.5, prior to 
lymphovenous valve formation, recapitulates this phenotype at E13.5 
(Kazenwadel et al., 2015). In contrast, Lyve1-Cre–mediated Hdac3 deletion in 
lymphatic vasculature causes blood-lymph separation failure between E17.5 
and P0 (Figure 2.2, C and I, and Figure 2.1G). Pan-endothelial Cre-
expressing mice (Tek-Cre mice) show recombinase activity in LEC precursors 
at E10.5, prior to lymphovenous valve formation (Srinivasan et al., 2007). 
However, Lyve1-Cre–expressing embryos reveal fully penetrant recombinase 
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activity within lymphovenous valves at E14.5, after lymphovenous valve 
formation (Crosswhite et al., 2016). These alternative genetic approaches 
reveal that failure of blood-lymph separation due to lymphovenous valve 
defects corresponds with the timing of endothelial Hdac3 ablation in both 
Lyve1-Cre and Tek-Cre mice. 
Overall, our study suggests that enhancer-specific epigenetic signatures are 
functional components of mechano-induced transcriptional responses during 
lymphatic valve development. Future studies will define the precise 
mechanotransduction and mechanosensory pathways that integrate 
extracellular signaling at enhancers during lymphatic vascular development. 
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Materials and Methods 
Mice. Tek-Cre (Kisanuki et al., 2001), Cdh5-Cre (Alva et al., 2006), Lyve1-Cre 
(Pham et al., 2010), Pf4-iCre (codon-improved Cre recombinase) (Tiedt et al., 
2007), and Gt(ROSA)26Sor (Soriano, 1999) reporter mice were obtained from 
The Jackson Laboratory. Hdac1fl/fl (Milstone et al., 2017), Hdac2fl/fl (Anokye-
Danso et al., 2011), and Hdac3fl/fl (Mullican et al., 2008) mice have been 
previously described. 
 
Antibodies and reagents. Detailed antibody information is provided in Table 
2.6. Biotinylated secondary antibodies, VECTASHIELD mounting medium, the 
VECTASTAIN Elite ABC Kit, and the DAB Peroxidase Substrate Kit were 
purchased from Vector Laboratories. Harris modified hematoxylin, eosin Y, 
ethanol, methanol, chloroform, glacial acetic acid, xylenes, paraformaldehyde, 
paraffin, potassium ferricyanide, potassium ferrocyanide, and deoxycholic 
acid were purchased from Thermo Fisher Scientific. X-Gal was purchased 
from Five Prime Therapeutics. Linear polyethylenamine (PEI) was purchased 
from Polysciences. The RNeasy Mini Kit and GST bead slurry were 
purchased from QIAGEN. Power SYBR Green PCR Master Mix, a Superscript 
First Strand Synthesis Kit, a TOPO-TA Cloning Kit, DMEM high-glucose with 
NA pyruvate, penicillin-streptomycin, horse serum, a CellsDirect One-Step 
qRT-PCR Kit, insulin-transferrin-selenium (ITS), epoxy M-450 dynabeads, and 
TRIzol were purchased from Life Technologies (Thermo Fisher Scientific). 
iScript Reverse Transcription Supermix was purchased from Bio-Rad. Passive 
lysis buffer and a dual-luciferase reporter assay kit were purchased from 
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Promega. BALB/c murine primary LECs, basal medium, and complete mouse 
endothelial cell medium were purchased from Cell Biologics. FBS, donkey 
serum, gelatin, rabbit serum, Evans blue dye, protease inhibitor mixture, and 
magnetic anti-Flag beads were purchased from MilliporeSigma. Agarose IgG 
and IgA bead slurry were purchased from Santa Cruz Biotechnology and Life 
Technologies (Thermo Fisher Scientific). µ-Slide VI 0.4 Luer was purchased 
from Ibidi. The EZ-ChIP Assay Kit was purchased from MilliporeSigma. The 
RecoverAll Total Nucleic Acid Isolation Kit was purchased from Thermo 
Fisher Scientific. The CellAmp Whole Transcriptome Amplification Kit and the 
Takara DNA Ligation Kit were purchased from Takara. Membrane slides and 
isolation caps were purchased from Molecular Machines & Industries. 
 
Plasmids. WT, c.1017+512del28, and c.1017+572C>T Gata2 intragenic 
enhancer fragments with flanking restriction enzyme sites were purchased as 
MiniGenes cloned into a pIDTSMART-AMP vector from Integrated DNA 
Technologies. The enhancer fragments were digested with MluI and XhoI, gel 
purified, and cloned into the pGL3-Promoter Luciferase Vector (Promega). All 
plasmids were verified by restriction analyses and sequencing (Eurofins MWG 
Operon). Lentiviral plasmids expressing Hdac3 shRNA, EP300 shRNA, Tal1 
shRNA, Ets1/2 shRNA, Gata2 shRNA, and scrambled shRNA controls were 
obtained from the University of Massachusetts shRNA Core Facility. Plasmids 
expressing human GFP, HDAC3, HDAC3HEBI, and HDAC3H134A, H135A have 
been previously described (Lewandowski et al., 2015; Sun et al., 2013). 
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Table 2.6 
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Imaging. Images of dissected embryos, mice, and tissue sample were 
captured using a Leica MZ10 F fluorescence stereomicroscope equipped with 
a ×0.7 C-mount, Achromat 1.0 × 90 mm objective, a SOLA light engine, a DS-
Fi1 color camera (Nikon), and NIS-Elements Basic Research software 
(Nikon). Stained section images were captured using a Nikon Eclipse 80i 
microscope equipped with CFI Plan Fluor ×4/×10/×20/×40 objective lenses, a 
SOLA light engine (Lumencor), a DS-Fi1 color camera, and NIS-Elements 
Basic Research software. Whole-mount immunostained images were 
captured using a Zeiss LSM710 confocal scanning microscope equipped with 
a W Plan-Apochromat ×20/1.0 DIC D = 0.17 M27 70-mm objective lens as 
previously described (Shin et al., 2016). Whole-mount immunostained 
mesenteric vessels were flat mounted onto histobond glass slides using 
VECTASHIELD mounting medium for immunofluorescence and imaged using 
a Nikon Eclipse 80i microscope or a Leica TCS SP5 II Laser Scanning 
Confocal microscope. Alexa Fluor 488 and 568 were simultaneously excited 
at 488 nm and 561 nm with confocal lasers, respectively. Emissions were split 
by an MBS 488/561/633 beam splitter and captured with 2 detection ranges 
(ch1: 493–536 nm, ch2: 576–685 nm). For nuclear staining, Hoechst was 
excited using a Chameleon Ti:Sapphire pulse laser (755 nm) (Coherent Inc.) 
and was emission detected at 387 to 486 nm. Image stacks of vertical 
projections were assembled using ImageJ software (NIH). 
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Histology. Embryos and tissues samples were fixed in 2% paraformaldehyde 
at 4°C overnight, ethanol dehydrated, embedded in paraffin, and sectioned at 
6- to 8-µm thickness using a Leica fully motorized rotary microtome. 
 
H&E staining. Formalin-fixed, paraffin-embedded tissue sections were 
deparaffinized in xylene and rehydrated through an ethanol gradient, followed 
by 2-minute Harris modified hematoxylin and 30-second eosin-Y staining. 
Slides were dehydrated with ethanol, cleared with xylene, and mounted with 
VECTASHIELD mounting medium. 
 
In vitro OSS experiments. Transiently transfected or infected murine primary 
LECs were seeded at confluence on µ-Slide VI 0.4 Luer, cultured for 24 
hours, and subjected to OSS (4 dynes/cm2, 4 Hz) in a parallel-plate flow 
chamber system (Ibidi Pump System; Ibidi) or under static conditions for 48 
hours. 
β-Gal staining. Embryos were dissected and placed in ice-cold 1× PBS and 
then fixed in 4% paraformaldehyde for 1 hour at 4°C. Embryos were washed 
in 1× PBS for 30 minutes at room temperature and then incubated in β-gal 
staining solution (5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, 
2 mM MgCl2, 0.04% NP-40, 0.01% deoxycholate, and 0.1% X-gal substrate in 
1× PBS) for 48 to 72 hours at 37°C in the dark. Embryos were then washed 3 
times for 20 minutes each in 1× PBS at room temperature and fixed overnight 
in 4% paraformaldehyde. 
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IHC. IHC was performed as we previously described (Lewandowski et al., 
2015). Briefly, slides with sections were deparaffinized and immersed in 
sodium citrate buffer (10 mM sodium citrate, 0.05% Tween-20, pH 6) or R-
buffer A (pH 6; Electron Microscopy Sciences) and placed in a 2100 Antigen 
Retriever (Aptum Biologics) for heat-induced antigen retrieval. IHC was 
conducted using a VECTASTAIN Elite ABC Kit and a DAB Peroxidase 
Substrate Kit (both from Vector Laboratories) according to the manufacturer’s 
guidelines. Sections were incubated with primary antibodies overnight at 4°C 
(Table 2.6). Biotinylated universal pan-specific antibody (1:62.5) (horse anti-
mouse/rabbit/goat IgG); biotinylated universal antibody (horse anti-
mouse/rabbit IgG); or biotinylated rabbit anti-rat IgG antibody (1:62.5) (all from 
Vector Laboratories) were used as secondary antibodies for 1 hour at 25°C 
according to the manufacturer’s instructions. For counterstaining, slides were 
rinsed and then incubated with 30% hematoxylin for 30 seconds after DAB 
development. All slides were ethanol dehydrated, cleared with xylenes, and 
mounted with VECTASHIELD mounting medium. For immunofluorescence 
staining, after antigen retrieval, sections were blocked in 10% donkey serum 
and 0.3% Triton X-100 in PBS for 1 hour at room temperature. Sections were 
then washed in PBS and coincubated with primary antibodies in 10% donkey 
serum and PBS overnight at 4°C (Table 2.6). Finally, slides were washed in 
PBS, incubated in Alexa Fluor 488– or 546/568–conjugated secondary 
antibodies (1:500) with Hoechst (1:1,000) for 1 hour at room temperature, 
rinsed in PBS, and mounted with VECTASHIELD mounting medium. 
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Cell culture, transient transfection, lentiviral infection, and luciferase assay. 
Murine primary LECs were maintained in complete mouse endothelial cell 
medium in a 37°C incubator with 5% CO2 according to the manufacturer’s 
protocol (Cell Biologics). All experiments were conducted using passage 3–6 
LECs. HEK293T cells were maintained in DMEM with 10% FBS, 100 mg/ml 
penicillin, and 100 mM/ml streptomycin in a 37°C incubator with 5% CO2. 
Subconfluent HEK293T cells were transfected in 100-mm plates with 5 µg 
lentiviral plasmid expressing the relevant cDNA or shRNA, 5 µg pCMV-dR8.2, 
2.5 µg pCMV-VSVG, and 5 µl PEI, in 10 ml of 2% FBS media. Media were 
changed to fresh FBS media (10 ml of 1%) 24 hours after transfection. 
Supernatant media were collected 24 hours later and filtered through a 40-µm 
cell strainer. Murine primary LECs were infected with fresh-filtered viral media 
supplemented with 10 µg/ml polybrene reagent. Murine primary LECs were 
transiently transfected using a PEI-based transfection protocol (Boussif et al., 
1995; Lewandowski et al., 2014; 2015; Longo et al., 2013). Each well of a 6-
well plate containing subconfluent (~60% confluent) LECs was transfected 
with a total of 1 µg plasmid DNA, including 0.5 µg WT or c.1017+512del28, or 
the c.1017+572C>T Gata2 intragenic enhancer pGL3-promoter luciferase 
vector, with or without 0.5 µg Hdac3 shRNA–expressing vector and 2 µl PEI 
(1 mg/ml in double-distilled H2O, pH 7.0), in 2 ml complete mouse endothelial 
cell medium. The PEI-DNA complex was incubated at room temperature for 
20 minute before adding it to LECs in a drop-wise manner. The DNA amount 
was maintained constant using pcDNA3.1(-) DNA. LECs were trypsinized and 
reseeded to a µ-Slide VI 0.4 Luer (~100% confluence) 24 hours after 
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transfection. Transiently transfected LECs were subjected to static or OSS 
conditions for 48 hours and lysed with passive lysis buffer. Lysates were 
analyzed using a dual luciferase reporter assay kit according to the 
manufacturer’s protocol (Promega). Luciferase activity was measured using a 
Berthold microplate reader according to the manufacturer’s guidelines. 
 
LCMD. LCMD was performed according to the manufacturer’s protocol 
(Molecular Machines & Industries). Briefly, embryos were dissected at E13.5 
in cold DEPC–treated 1× PBS, fixed in methacam (60% methanol, 30% 
chloroform, 10% glacial acetic acid) overnight at 4°C, ethanol dehydrated, 
embedded in paraffin, sectioned at 8-µm thickness, and mounted onto 
membrane slides. Tissue sections were deparaffinized in xylene and 
rehydrated through an ethanol gradient, followed by a 10-second hematoxylin 
staining. LCMD was performed on an MMI CellCut System equipped with a 
fixed UV laser with a higher pulse rate using MMI CellTools software, phase-
contrast objectives, and an MMI CellCamera (all from Molecular Machines & 
Industries). Microdissected tissue was collected directly into an adhesive MMI 
isolation cap. 
 
ChIP. ChIP experiments were performed as previously described 
(Lewandowski et al., 2014). Briefly, primary LECs subjected to OSS or static 
conditions were pooled (total ~1 × 106 cells), cross-linked for 15 minutes in 
cross-linking solution (1% formaldehyde, 1.5 mM ethylene glycol-bis 
succinimidyl succinate, 20 mM sodium butyrate, 10% FBS), and then 
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quenched with 125 mM glycine solution for 5 minutes, followed by 2 washes 
with 1× PBS. Chromatin fragmentation was performed by sonication in ChIP 
SDS lysis buffer (50 mM Tris-HCl, pH 8.0, 10 mM EDTA, 1% SDS, 1× 
protease inhibitors) using the Branson Sonifier 250 (40% power amplitude, 
120-second). Proteins were immunoprecipitated in ChIP dilution buffer (0.01% 
SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl, pH 8.0, 167 mM 
NaCl, 20 mM sodium butyrate, 1× protease inhibitor) using IgG, Hdac3, 
Ep300, Tal1, Ets1/2, Gata2, or H3K27ac primary antibody. Specificity of the 
primary antibody at the relevant locus was determined using an IgG control 
antibody. Immunoprecipitated antibody-chromatin complexes were washed 
twice with low-salt wash buffer (20 mM Tris-HCl, pH 8.0, 150 mM NaCl, 2 mM 
EDTA, 0.1% SDS, and 1% Triton X-100), followed by 2 washes with lithium 
chloride wash buffer (10 mM Tris-HCl, pH 8.0, 250 mM LiCl, 1 mM EDTA, 1% 
deoxycholate, 1% Nonidet P-40) and TE buffer (10 mM Tris-HCl, pH 8.0, 1 
mM EDTA). After removing the wash buffer, cross-linking was reversed at 
65°C overnight in proteinase K buffer (20 mM Tris-HCl, pH 7.5, 5 mM EDTA, 
50 mM NaCl, 1% SDS, 20 mM sodium butyrate, 50 µg/ml proteinase K). The 
following day, DNA was purified with phenol/chloroform/isoamyl alcohol. 
Using purified precipitated DNA, enrichment of the target sequences was 
measured by ChIP-qPCR using primers designed against the murine Gata2 
intragenic enhancer. 
 
RNA isolation and ChIP-qPCR. Chyle-filled mesenteric lymphatic vessels 
originating from mesenteric lymph nodes were identified and dissected from 
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P5 mice. Total RNA from cultured murine primary LECs or isolated 
mesenteric lymphatic vessels, and formalin-fixed, methacam-fixed, paraffin-
embedded (MFPE) tissue was isolated using the CellAmp Whole 
Transcriptome Amplification Kit and the RecoverAll Total Nucleic Acid 
Isolation Kit, respectively. Total RNA was reverse transcribed using iScript 
Reverse Transcription Supermix (Bio-Rad) or the CellAmp Whole 
Transcriptome Amplification Kit (Takara) according to the manufacturers’ 
protocols. Expression of relevant transcripts was measured by ChIP-qPCR 
using SYBR Green PCR Master Mix as previously described (Lewandowski et 
al., 2015). Signals were normalized to corresponding GAPDH controls and 
are represented as relative expression ratios of the experimental samples 
relative to controls. 
Whole-mount IHC. Mesentery tissues from P5 mice were dissected, fixed in 
4% paraformaldehyde overnight at 4°C, washed in 1× PBS twice at 4°C for 30 
minutes, and dehydrated through a methanol gradient. The samples were 
then incubated with antibodies against Vegfr3 (1:200) and Hdac3 (1:50) or 
Prox1 (1:100) overnight at 4°C. Finally, tissue samples were washed in PBS, 
incubated overnight at 4°C in Alexa Fluor 488– or 546/568–conjugated 
secondary antibodies (1:200), with or without Hoechst (1:1,000), rinsed in 
PBS, and then imaged using confocal microscopy. 
 
Evans Blue dye lymphangiography. Evans blue dye (50 µl of 1%, 10 mg/ml), 
prepared in 1× PBS (pH 7.4), was injected into the left hind footpad of 
anesthetized mice, with the needle pointed in the dorsal direction. Fifteen 
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minutes after injection, the mice were euthanized and dissected to examine 
lymphatic vessels, the thoracic duct, and lymph nodes of interest. 
 
Platelet count. Approximately 100 µl of blood was drawn from each 
anesthetized P5 pup via intracardiac puncture and collected in 200 µl citrate-
phosphate-dextrose (CPD) buffer (16 mM citric acid [anhydrous], 102 mM 
trisodium citrate, 18.5 mM NaH2PO4, 142 mM D-glucose, pH 7.4) as 
described previously (76). Platelet counts were obtained and calculated using 
an automated cell counter (Beckman Coulter; Ac.T 8). 
 
Immunoprecipitation and Western blot analysis. Samples were homogenized 
in immunoprecipitation buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.5% 
Nonidet P-40, 1 mM EDTA, and 1 mM DTT) containing 1 mM PMSF and a 
protease inhibitor mixture. The homogenized samples were sonicated using a 
Branson 250 Digital Sonifier with 1-second-on and 1-second-off pulses at 
40% power amplitude for 15 seconds. Precleared lysates were incubated with 
the relevant primary antibody–conjugated magnetic beads for 16 hours at 
4°C. Immune complexes were collected, washed 4 times with 
immunoprecipitation buffer, and applied to 4%–12% SDS-polyacrylamide gels 
for Western blot analysis before transferring to PVDF membranes. Primary 
antibodies against HDAC3 (1:1,000), Tal1 (1:1,000), Gata2 (1:1,000), and 
Ets1/2 (1:1,000) were used and visualized by chemiluminescence using HRP-
conjugated secondary antibodies. Blots were probed with α-tubulin (1:1,000) 
for the loading control. 
	 116	
 
Statistics. Statistical significance was determined using a 2-tailed Student’s t 
test, a χ2 test, or a 1-way ANOVA with Sidak’s multiple comparisons test 
(GraphPad Prism 7.0; GraphPad Software). A P value of less than 0.05 was 
considered significant. 
 
Study approval. The University of Massachusetts Medical School is 
accredited by the Association for Assessment and Accreditation of Laboratory 
Animal Care (AAALAC) International and follows the Public Health Service 
Policy for the Care and Use of Laboratory Animals. Animal care was provided 
in accordance with the procedures outlined in the Guide for the Care and Use 
of Laboratory Animals (National Academies Press, 2011). The IACUC of the 
University of Massachusetts Medical School approved all animal use 
protocols. 
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Chapter III: Discussion & Future Directions 
 
The elucidation of in vivo developmental and tissue-specific functions of 
histone modifying enzymes is an active area of investigation. Histone 
deacetylases (Hdacs) play critical roles during embryonic organogenesis 
including development of the cardiovascular, nervous and musculoskeletal 
systems (Haberland et al., 2009b). Here we identified a novel and unexpected 
endothelial specific function of Hdac3, during lymphovenous and lymphatic 
valve formation. Mice lacking endothelial Hdac3, but not Hdac1 or Hdac2, 
exhibit defective blood-lymphatic separation, lymphatic dysfunction and 
lethality. This is important, as no other histone-modifying enzyme, including 
HDACs, has been shown to affect lymphatic system. Surprisingly, endothelial 
ablation of Hdac3 did not cause any overt defects in arterial or venous 
development. In contrast, mice lacking Hdac7 exhibit severe vascular defects, 
suggesting a specific role for Class II HDACs during vascular development 
(Chang et al., 2006).  Similarly, Hdac6, a class II HDAC, regulate blood vessel 
formation in zebrafish by deacetylation of an actin- remodeling protein 
cortactin (Kaluza et al., 2011). However, mice lacking Hdac6 apparently do 
not show any vascular defects (Kaluza et al., 2011).  
Separation of blood and lymphatic vascular systems is necessary for survival 
and occurs early during lymphatic vascular development. Two key 
mechanisms, established embryonically, are required to attain the separation 
of the blood and lymphatic vascular systems. First, the development of 
lymphovenous valves at the junction between the cardinal vein and lymph sac 
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around embryonic day 12 (E12), which prevents the backflow of venous blood 
into the lymphatic system. Indeed, mice with defective lymphovenous valves 
exhibit blood-filled lymphatic vasculature at various stages of embryonic 
development (Turner et al., 2014; Geng et al., 2016; Kazenwadel et al., 2015; 
Srinivasan et al., 2011). Second, platelet mediated inter-vascular hemostasis 
at the junction of the cardinal vein and budding lymph sacs around E11.5 is 
essential for blood-lymph separation. Defective lymphovenous hemostasis in 
mouse models causes blood filled lymphatic vessels as early as E11.5 
(Abtahian et al., 2003). However, these mice show normal lymphovenous 
valve development, suggesting that lymphovenous hemostasis is not required 
for lymphovenous valve development (Hess et al., 2013). Endothelial Hdac3 
deficient mice show anomalous lymphovenous valve development and blood 
filled lymphatic vessels as early as E12.5. Interestingly, lymphatic endothelial 
cell specific Hdac3 ablation causes failure of blood-lymph separation during 
late embryonic gestation. The variability in the timing of appearance of blood 
filled lymphatics in the different Cre models is likely due to timing of activation 
of Cre-recombinase and Hdac3 deletion with earlier activity and deletion seen 
in Tie2-Cre model versus that in Lyve1-Cre models. Most endothelial specific 
Cre-recombinase mice have variable amounts of expression in hematopoietic 
cells such as platelets and macrophages, hence, it is pertinent to establish the 
specific cell type in which Hdac3 functions to regulate blood-lymph separation 
(Joseph et al., 2013). Mice lacking Hdac3 in lymphatic endothelial cells exhibit 
anomalous lymphovenous valve morphogenesis and failure of blood lymph 
separation, suggesting that Hdac3 functions in a lymphatic endothelial cell 
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autonomous manner during lymphovenous valve development. Consistent 
with this, platelet or macrophage specific Hdac3 knockout mice show normal 
blood-lymph separation.  
 Platelet mediated lymphovenous hemostasis is critical for maintenance 
of blood lymph separation throughout postnatal life (Hess et al., 2013). 
Whether lymphovenous valves and Hdac3 are required for such maintenance 
is not known and requires further study. Experiments involving transfer of 
hematopoietic cells deficient in Hdac3; into wild type mice depleted of 
hematopoietic cells, is an additional way of testing whether Hdac3 functions in 
hematopoietic cells to effect blood lymph separation. Although no difference in 
expression of podoplanin was noted in the lymphovenous junction region, it is 
possible that lymphovenous hemostasis maybe impacted by altering the 
expression of other endothelial ligands of Clec2 as has been proposed 
(Suzuki-Inoue et al., 2010). Taken together, our results provide the first 
evidence for histone-modifying enzymes in regulation of lymphovenous valve 
development and blood lymph separation. 
In addition to defective lymphovenous valves, we observed significant 
reduction in valve number in murine mesenteric lymphatic vessels lacking 
Hdac3. Several reports have highlighted common genes that regulate 
development of both lymphovenous valves and lymphatic valves (Geng et al., 
2016; Kazenwadel et al., 2015; Martin-Almedina et al., 2016; Zhang et al., 
2015). For instance, conditional ablation of Gata2 or Foxc2 in endothelial cells 
perturbs both lymphovenous and lymphatic valve formation (Cha et al., 2016; 
Geng et al., 2016). In addition, physiological factors such as fluid pressure 
	 120	
and shear stress also regulate development, maturation, and function of the 
lymphatic system (Schwartz and Simons, 2012). Embryonic lymphatic vessels 
coordinate their growth in respond to changes in interstitial fluid pressure 
(Planas-Paz et al., 2011). Lymphatic flow, which starts prior to lymphatic valve 
initiation, is an important physiological stimulus that initiates lymphatic valve 
development in collecting lymphatic vessels (Sabine et al., 2012). A recent 
study showed that presence of blood in developing lymphatic vessels could 
impair lymph flow and hence perturb lymphatic vessel valve formation (Sweet 
et al., 2015). Endothelial Hdac3 deficient mice display blood filled lymphatic 
vessels and impaired lymphatic valve formation raising the possibility that 
defective lymphatic valve formation could be secondary to blood impeding 
forward lymph flow. However, several points argue against this possibility and 
suggest that Hdac3 is a primary regulator of lymphatic valve development. 
First, blood filled lymphatic vessels in endothelial Hdac3 deficient mice appear 
after the initiation of mesenteric lymphatic valve formation. Second, 
mesenteric vessel remodeling appears unaffected in endothelial Hdac3 
deficient mice in contrast to Clec2 deficient mice. Finally, our studies using 
murine lymphatic endothelial cells subjected to oscillatory shear stress 
suggest that Hdac3 regulates the transcription of Gata2, a critical gene 
required for lymphatic valve formation. 
           Lymphatic valves are often formed in vessel regions subject to 
oscillatory shear stress (OSS). Consistent with this, cultured LECs subjected 
to OSS alter their cellular morphology and upregulate expression of genes 
critical for lymphatic valve formation (Sabine et al., 2012). Hdac3-deficient 
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LECs fail to upregulate these critical genes in response to OSS, suggesting 
requirement of Hdac3 function during OSS-dependent transcriptional 
activation.  
            In response to OSS, our data show that Hdac3 interacts with 
transcription factors Gata2, Tal1 and Ets1/2. The exact mechanism by which 
Gata2 or Tal1 or Ets1/2 interacts with and recruits Hdac3 to chromatin in a 
flow responsive manner remains to be determined. Reversible, post-
translational modifications of proteins are a common mechanism to regulate 
protein-protein interactions in response to signaling pathways, including 
external stimuli (Duan and Walther, 2015). Notch, BMP and retinoic acid 
signaling pathways have been shown to affect Gata2 transcription and/or 
activity in different contexts (Oren, 2005; Robert-Moreno, 2005; Tsuzuki et al., 
2004). Notch1 directly promotes Gata2 transcription in embryonic hemogenic 
endothelium (Robert-Moreno, 2005). Gata2 via its association with Retinoic 
acid receptor alpha (RARα) becomes responsive to RA signaling (Tsuzuki et 
al., 2004). Interestingly, Notch and BMP9 signaling pathways regulate 
lymphatic valve development, however, whether they affect Gata2 
transcription in lymphatic endothelial cells is not known (Levet et al., 2013; 
Murtomaki et al., 2014). Gata2 is acetylated by p300 and GCN5 acetyl 
transferases with consequent increases in its DNA binding ability (Hayakawa 
et al., 2003). Although our studies suggest that Hdac3 functions in a 
deacetylase-independent manner in regulating transcription of Gata2, it 
remains to be determined whether Hdac3 interaction with Gata2 is affected by 
its acetylation. 
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           Genome-wide associations studies (GWAS) implicate variations in 
non-coding DNA elements as potential drivers of disease (Maurano et al., 
2012). In addition, non-coding elements account for a large fraction of 
evolutionarily constrained sequences suggesting that they may serve 
important biological functions. Mutations or deletions encompassing 
enhancers and other cis-regulatory elements have been implicated in disease 
causation (Smith and Shilatifard, 2014). For example, a single nucleotide 
change in ZRS enhancer results in altered sonic hedgehog (SHH) expression 
resulting in pre-axial polydactyly, a developmental defect (Lettice, 2003). 
Genome-wide ChIP-Seq analysis of p300 binding together with other histone 
modifications such as H3K4me1 (mono-methylated H3 Lysine 4) and 
H3K27ac have been used to identify active enhancers in a tissue specific 
manner (Visel et al., 2009; Heintzman et al., 2007). Studies that have 
determined genome-wide binding profiles of Hdac3, across different cell 
types, have shown that Hdac3 is bound mostly to intergenic regions and 
enhancer elements (Zhang et al., 2016; Mullican et al., 2008). Our data show 
that Hdac3 binds to and regulates the activity of an evolutionarily conserved 
enhancer element critical for Gata2 transcription. Additional studies, probing 
genome wide chromatin binding of Hdac3 together with chromatin binding 
profiles of p300, H3K4me1 and H3K27ac within lymphatic endothelial cells will 
help identify other potential enhancers critical for lymphatic vascular 
development and function.  
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